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Summary
An estimated one third of the world’s population is infected with Mycobacterium tuberculosis, and nearly 9 million persons 
develop disease caused by M. tuberculosis each year. Although tuberculosis (TB) occurs predominantly in resource-limited coun-
tries, it also occurs in the United States.
During 1985–1992, the United States was confronted with an unprecedented TB resurgence. This resurgence was accompa-
nied by a rise in multidrug-resistant TB (MDR TB), which is defined as TB that is resistant to the two most effective first-line 
therapeutic drugs, isoniazid and rifampin. In addition, virtually untreatable strains of M. tuberculosis are emerging globally. 
Extensively drug-resistant (XDR) TB is defined as MDR TB that also is resistant to the most effective second-line therapeutic 
drugs used commonly to treat MDR TB: fluoroquinolones and at least one of three injectable second-line drugs used to treat TB 
(amikacin, kanamycin, or capreomycin). XDR TB has been identified in all regions of the world, including the United States.
In the United States, the cost of hospitalization for one XDR TB patient is estimated to average $483,000, approximately twice 
the cost for MDR TB patients. Because of the limited responsiveness of XDR TB to available antibiotics, mortality rates among 
patients with XDR TB are similar to those of TB patients in the preantibiotic era.
In January 1992, CDC convened a Federal TB Task Force to draft an action plan to improve prevention and control of drug-
resistant TB in the United States (CDC. National action plan to combat multidrug-resistant tuberculosis. MMWR 1992;41([No. 
RR-11]). In November 2006, CDC reconvened the Task Force to draft an updated action plan to address the issue of MDR TB 
and XDR TB. Task Force members were divided into nine response areas and charged with articulating the most pressing prob-
lems, identifying barriers to improvement, and recommending specific action steps to improve prevention and control of XDR TB 
within their respective areas.
Although the first priority of the Federal TB Task Force convened in 2006 was to delineate objectives and action steps to address 
MDR TB and XDR TB domestically, members recognized the necessity for TB experts in the United States to work with the inter-
national community to help strengthen TB control efforts globally. TB represents a substantial public health problem in low- and 
middle-income countries, many of which might benefit from assistance by the United States. In addition, the global TB epidemic 
directly affects the United States because the majority of all cases of TB and 80% of cases of MDR TB reported in the United States 
occur among foreign-born persons. For these reasons, the Action Plan also outlines potential steps that U.S. government agencies 
can take to help solve global XDR TB problems. Unless the fundamental causes of MDR TB and XDR TB are addressed in the 
United States and internationally, the United States is likely to experience a growing number of cases of MDR TB and XDR TB 
that will be difficult, if not impossible, to treat or prevent.
The recommendations provided in this report include specific action steps and new activities that will require additional funding 
and a renewed commitment by government and nongovern-
ment organizations involved in domestic and international TB 
control efforts to be implemented effectively. The Federal TB 
Task Force will coordinate activities of various federal agencies 
and partner with state and local health departments, nonprofit 
and TB advocacy organizations in implementing this plan 
to control and prevent XDR TB in the United States and to 
contribute to global efforts in the fight against this emerging 
public health crisis.
The material in this report originated in the National Center for HIV/
AIDS, Viral Hepatitis, STD, and TB Prevention, Kevin Fenton, MD, 
PhD, Director, and the Division of Tuberculosis Elimination, Kenneth 
G. Castro, MD, Director.
Corresponding preparer: Philip LoBue, MD, Division of TB 
Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, 
and TB Prevention, CDC, 1600 Clifton Road, NE, MS E-10, Atlanta, 
GA 30333. Telephone: 404-639-8120; Fax: 404-639-8604; E-mail: 
plobue@cdc.gov.
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Introduction
Global Health Burden of Tuberculosis
Tuberculosis (TB) is among the most common infectious dis-
eases and frequent causes of death worldwide (1). TB is caused 
by Mycobacterium tuberculosis and is spread most commonly 
by airborne transmission. M. tuberculosis can affect any part 
of the body but is found most often in the lungs. Persons with 
pulmonary TB generally have a cough that produces small air-
borne droplet nuclei containing tubercle bacilli that can remain 
in the air for hours. Vulnerable persons exposed to tubercle 
bacilli in airborne droplets might become infected. The major-
ity of persons who become infected remain noncontagious and 
without a cough or other symptoms. These persons have latent 
M. tuberculosis infection (LTBI) and can be treated with a single 
drug (isoniazid) for 9 months to prevent disease.
Infected persons who do not have underlying medical 
problems and do not receive LTBI treatment have a 5%–10% 
lifetime risk for progressing to TB disease (2). However, the 
risk for disease progression increases substantially in the pres-
ence of immunosuppression, such as that caused by the human 
immunodeficiency virus (HIV) and immunosuppressive medi-
cations (2). Persons with pulmonary TB can be cured with a 
6-month course of antibiotics that includes isoniazid, rifampin, 
pyrazinamide, and ethambutol during the first 2 months. In 
the United States, diagnosis and treatment for TB is accessible 
and effective (3). However, many developing countries have 
limited resources to diagnose TB illness and treat persons with 
TB. Worldwide, 2 billion persons (one third of the world’s 
population) are thought to have LTBI. Nearly 9 million persons 
develop TB disease each year, and close to 2 million TB-related 
deaths occur annually (1). In the United States, approximately 
13,000 new cases of TB are reported annually, and 650 persons 
die from TB each year (4). TB is the leading cause of mortality 
among persons infected with HIV (5).
Emergence of Drug-Resistant 
Tuberculosis
During 1985–1992, the United States experienced an 
unprecedented TB resurgence marked by a substantial number 
of patients with TB who did not respond to treatment and who 
eventually died (6). Physicians and epidemiologists quickly 
determined that these persons had multidrug-resistant TB 
(MDR TB), which is defined as TB that is resistant to both 
isoniazid and rifampin (7). Although persons with MDR TB 
usually can be treated effectively by relying on second-line 
drugs (amikacin, kanamycin, or capreomycin), these have more 
side effects and are more expensive and less effective than first-
line drugs and require regimens lasting 18–24 months (3). In 
addition, the cure rate for persons with MDR TB is 50%–60%, 
compared with 95%–97% for persons with drug-susceptible 
TB (3). In response to several MDR TB outbreaks in hospitals 
and correctional facilities in New York and Florida during 
1988–1991 (8,9), CDC convened a Federal TB Task Force* 
with representatives from multiple U.S. agencies† to produce 
recommendations for a nationwide response to the MDR TB 
outbreaks. In June 1992, the Federal TB Task Force published 
an action plan that provided a framework for response and 
specific action steps for state and local health departments 
and federal agencies (7). These action steps were grouped 
into nine categories: 1) surveillance and epidemiology, 2) 
laboratory diagnosis, 3) patient management, 4) screening and 
preventive therapy, 5) infection control, 6) outbreak control, 
7) program evaluation, 8) information dissemination/training 
and education, and 9) research. Emergency federal funding was 
appropriated to CDC in 1993 and again in 1994 to allow the 
Federal TB Task Force and state and local health departments 
to implement certain parts of the plan. For example, CDC 
investigative teams were deployed to assist local programs in 
defining and organizing appropriate response to MDR TB out-
breaks (CDC, personal communication, 2007). State and local 
health departments enhanced diagnostic laboratory capacity, 
increased the sensitivity of their surveillance systems, improved 
infection-control practices, and reemphasized the need for 
optimal treatment of all forms of TB to prevent the develop-
ment and further transmission of MDR TB. Other federal 
agencies that are members of the task force also contributed 
substantially to implementation of the plan; a description of 
their activities follows.
The need for increased biomedical research and product 
development for TB was recognized by the National Institutes 
of Health (NIH) as part of the implementation of the 1992 
Action Plan. The National Institute for Allergy and Infectious 
Diseases (NIAID) established extramural and intramural 
research programs in all areas of fundamental, translational, 
and clinical research in TB to create a platform of knowledge 
and the research tools needed to study M. tuberculosis and its 
interaction with the host and to characterize TB in animal 
models and humans. In June 2007, NIAID released a research 
agenda describing the specific biomedical research challenges 
and priorities that should be addressed in response to the 
emergence of drug-resistant TB (10).
* A list of the members of the task force as of March 2007 appears on page 43 
of this report.
† CDC, Food and Drug Administration, National Institutes of Health, Health 
Resources and Services Administration, Bureau of Prisons, Occupational Safety 
and Health Administration, Health Care Financing Administration, Indian 
Health Service, and National Institute on Drug Abuse.
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The National Heart, Lung, and Blood Institute (NHLBI) 
supported studies with a strong emphasis on pulmonary TB, 
including complications through coinfection with HIV, and 
developed a training curriculum in TB for health profession-
als at medical institutions through the National Tuberculosis 
Curriculum Consortium (NTCC) (11,12). The Fogarty 
International Center (FIC) supported TB research and research 
training for developing country scientists through collaborative 
grants with U.S. institutions (13). The Eunice Kennedy Shriver 
National Institute of Child Health and Human Development 
(NICHD) focused on international clinical research for 
optimizing TB treatment in children and women coinfected 
with HIV (14). The more recently created National Institute 
of Biomedical Imaging and Bioengineering (NIBIB) has a 
substantial investment in diagnostic platform technologies 
(point-of-care and imaging) that can help improve TB diag-
nosis through advances in medical imaging methods (15).
In May 1994, the Food and Drug Administration (FDA) 
approved Rifater (a fixed-dose combination of rifampin, iso-
niazid, and pyrazinamide) to facilitate patient adherence with 
lengthy and complex multidrug therapy (16). In addition, FDA 
granted a priority new drug application review for the drug 
rifapentine, which was approved in July 1998 for the treat-
ment of TB (17). In 1993, the United States Marshals Service 
(USMS) established a formal medical program for prisoners 
with TB (USMS, personal communication, 2007). As part of 
this activity, USMS drafted a series of advisory memoranda to 
provide education information and guidance to USMS field 
offices to support TB screening for staff and prisoners. USMS 
also collaborated with the Texas Department of Health to 
conduct presentations on TB control in correctional facilities 
highlighting patient tracking and follow-up issues that arise 
when transferring prisoners between and outside jurisdictions. 
The Department of Housing and Urban Development (HUD) 
developed web-based information and training activities on 
acquired immune deficiency syndrome (AIDS) and TB (HUD, 
personal communication, 2007).
Since 1998, with the creation of specific international TB 
programs (e.g., directly observed treatment, short-course 
[DOTS] expansion; research; training; and TB/HIV coin-
fection), the U.S. Agency for International Development 
(USAID) has provided technical and financial support to 
strengthen TB control programs worldwide (18). USAID also 
has supported drug-resistance surveys with biannual global 
reports and pilot programs to optimize MDR TB treatment 
and the Green Light Committee (GLC), which helps coun-
tries gain access to high-quality second-line TB drugs so they 
can provide treatment for persons with MDR TB (19). More 
recently, the Division of Immigration Health Services (DIHS) 
of the Health Resources and Services Administration (HRSA) 
implemented a national TB Continuity of Care Program for 
persons who are detained by U.S. Immigration and Customs 
Enforcement (ICE) agents in the Department of Homeland 
Security (DHS) and who are to be deported before completing 
TB therapy (20); in October 2007, DIHS was transferred from 
HRSA to ICE. In addition, U.S. government agencies have 
worked with their counterparts in Mexico and in U.S. state 
agencies to develop initiatives (e.g., Ten Against TB) to address 
TB, including drug-resistant TB, along the U.S.-Mexico border 
(21). During 1993–2007, as a result of implementation of the 
1992 Action Plan, the reported annual incidence of MDR TB 
in the United States declined 75%, from 485 cases in 1993 to 
119 cases in 2007 (4).
Emergence of Extensively 
Drug-Resistant Tuberculosis
Since 1993, both incidence of TB and the total number of 
TB cases in the United States have decreased, although the rate 
of decline has slowed since 2000. Worldwide, the number of 
TB cases has continued to increase, but the incidence rate has 
decreased since 2003. Recently, highly drug-resistant forms 
of TB have emerged worldwide. In 2006, CDC, the World 
Health Organization (WHO) and the International Union 
Against Tuberculosis and Lung Disease (IUATLD) reported the 
results of a survey regarding drug-resistant TB conducted by 
25 reference laboratories comprising the Global Supranational 
TB Reference Laboratory Network (2000–2004), the National 
TB Surveillance System in the United States (1993–2004), 
the national reference laboratory of South Korea (2004), and 
the national MDR TB patient registry in Latvia (2000–2002) 
(22). The findings indicated that 20% of M. tuberculosis isolates 
were MDR, and 2% also were resistant to multiple second-line 
drugs. This highly resistant form of TB was identified in every 
region of the world, including the United States, where 4% of 
MDR TB isolates also were resistant to multiple second-line 
drugs. In a report published in 2006, this highly resistant form 
of TB was named extensively drug-resistant TB (XDR TB) 
(22). XDR TB is a subset of MDR TB that is resistant both to 
isoniazid and rifampin and to any fluoroquinolone drug and 
at least one of three second-line injectable drugs (amikacin, 
kanamycin, or capreomycin) (23).
The emergence of XDR TB raises concerns about the possi-
bility of epidemics of virtually untreatable TB. Such epidemics 
could result in excessive mortality and substantial financial 
and infrastructure burden for public health and TB control 
programs. XDR TB is much more expensive to treat, with 
hospitalization costs in the United States estimated to aver-
age $483,000 per case. A major outbreak of XDR TB in the 
United States would constitute a substantial drain on public 
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health resources and could quickly deplete the existing state 
and local TB budgets and have a negative impact on progress 
toward TB elimination. This is especially true in an era of 
diminishing resources for TB control at the national, state, and 
local levels (6). Treatment failures and subsequent death are 
more common among patients with XDR TB, and the drugs 
available to treat XDR TB are associated with serious adverse 
effects. Because persons who are infected with HIV or who have 
other immune-compromising conditions (e.g., diabetes) are 
more vulnerable to progressing to active TB disease, infection 
with XDR TB is of particular concern among these persons. 
In countries with high rates of HIV and limited health-care 
resources, substantial numbers of XDR TB cases are likely pres-
ent. As of April 2007, South Africa (where HIV prevalence was 
estimated at 10.8% in 2005) had reported 352 cases of XDR 
TB, with the actual prevalence likely being much higher (24) 
because cultures and susceptibility testing are performed on 
only a small fraction of TB patients, and many drug-resistant 
cases will go undetected.
Methodology
After an outbreak of XDR TB among HIV-infected persons 
in Kwazulu Natal, South Africa, reported in August 2006, 
urgent expert consultations were organized by the South 
African Medical Research Council (SAMRC) and WHO in 
September and October 2006 (25). The result of these con-
sultations was the 2007 publication of a global MDR TB and 
XDR TB response plan with eight overarching objectives (26). 
Several U.S. government agencies, including CDC, partici-
pated in the expert consultations. The U.S. Federal TB Task 
Force was recognized as the appropriate venue to coordinate 
U.S. involvement in the global response to XDR TB.
In November 2006, following participation in the SAMRC 
and WHO XDR TB consultations, CDC convened members 
of the Federal TB Task Force to discuss the emergence of XDR 
TB and coordinate U.S. government agency involvement in 
the domestic and international response to this problem. After 
several teleconferences, the Task Force agreed that a U.S. gov-
ernment agency action plan should be written. The action plan 
that had been published in 1992 to respond to MDR TB was 
selected as a basis for drafting the XDR TB response plan (7). 
Several members of the 2006 Task Force also had contributed 
to the 1992 Action Plan to combat MDR TB. This MDR 
TB expertise contributed substantially to a well-informed 
and effective discussion and the creation of an Action Plan to 
Combat Extensively Drug-Resistant TB. As had occurred in 
the process to create the 1992 Action Plan, members of the 
Federal TB Task Force were divided into sections to address 
critical areas of response. The 1992 action plan distributed 
the objectives and implementation steps needed to address 38 
problems among nine response areas (surveillance and epide-
miology, laboratory diagnosis, patient management, screening 
and preventive therapy, infection control, outbreak control, 
program evaluation, information dissemination/training and 
education, and research). Although largely overlapping with 
the 1992 action plan, the response areas for the XDR TB 
plan were reorganized as follows: 1) diagnostic laboratory; 2) 
surveillance, epidemiology, and outbreak investigations; 3) 
infection control; 4) clinical and programmatic interventions; 
5) ethical and legal issues; 6) communication and education; 7) 
research; 8) partnerships; and 9) cost analysis. These response 
areas also are closely aligned with WHO’s seven-point Global 
Action Plan to Combat XDR TB (26), which calls for public 
health authorities to 1) conduct rapid surveys of XDR TB to 
determine the burden, 2) enhance laboratory capacity with 
an emphasis on rapid drug-sensitivity testing, 3) improve the 
technical capacity of clinical and public health practitioners 
to respond effectively to XDR TB outbreaks and manage 
patients, 4) implement infection-control precautions, 5) 
increase research support for TB drug development, 6) increase 
research support for rapid diagnostic test development, and 
7) promote universal access to antiretroviral drugs under joint 
TB/HIV activities. In addition, the implementation steps were 
renamed “action steps.”
In January 2007, each subgroup of the Federal TB Task Force 
that was responsible for addressing a critical response area began 
by reviewing the relevant sections of the 1992 action plan to 
determine which problems, objectives, and action (formerly 
implementation) steps needed to be deleted or updated and 
revised. The subgroups also determined if gaps existed requiring 
the identification of additional problems, objectives and action 
steps. In particular, because the 1992 plan had focused primar-
ily on domestic MDR TB, the subgroups were instructed to 
expand the scope of the new plan to address the role of U.S. 
government agencies in the international response to XDR 
TB. To reflect this distinction, the new plan labels objectives 
as domestic, international, or both. The expanded scope and a 
greater emphasis on detail resulted in a substantial increase in 
the number of problems, objectives, and action steps identified 
compared with the 1992 plan. For example, the number of 
problems increased from 38 in 1992 to 67 in the current plan. 
An emphasis also was placed on being as inclusive as possible 
when designating lead federal agencies and potential external 
partners. To provide a basis for revisions, the subgroup mem-
bers reviewed pertinent literature published since 1992, which 
is substantially more voluminous, especially for drug-resistant 
TB, compared with that available before 1992, and available 
unpublished data. After drafts of the sections were completed, 
the sections were compiled into a single document that was 
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distributed to the entire Federal TB Task Force for review and 
comment. In June 2007, the Federal TB Task Force met in 
Rockville, Maryland, to make additional revisions, especially 
to eliminate redundancies between sections. These revisions 
were incorporated into a final draft that was submitted for 
multiple agency clearance in September 2007.




The diagnosis of XDR TB is established by laboratory meth-
ods. Accurate, reliable, and prompt TB laboratory services 
should be coordinated fully with provider and public health 
practitioners caring for persons with TB. Test results must be 
available in a time frame that allows clinicians to make prompt 
and informed patient management decisions. For this goal to 
be met, laboratory capacity for the diagnosis of TB and the 
detection of drug resistance must be rapidly enhanced, both 
in the United States and worldwide. Adequate infrastructure 
must be built where it does not exist, a stable and well-trained 
work force must be developed and maintained, and a systems 
approach (27) must be implemented to maximize efficiency 
and proficiency. Laboratory methods and reporting, especially 
for susceptibility to second-line drugs, should be standardized 
through expert consensus. Rapid tests for TB diagnosis and 
drug-susceptibility testing on the basis of newer molecular 
methods must be evaluated promptly to determine their fea-
sibility, especially for low-resource settings, and, if appropri-
ately validated, their use should be promoted and facilitated. 
Internationally, competent, high-quality reference laboratory 
services with capacity to perform required testing of samples 
and to report results in a prompt fashion to providers and 
health officials must be available to jurisdictions in need.
Surveillance, Epidemiology, and 
outbreak Investigation
Domestic XDR TB surveillance must include accurate 
and complete reporting of second-line drug-susceptibility 
testing, real-time reporting, and active case finding. Central 
notification of MDR TB and XDR TB is essential to identify 
cross-jurisdictional issues and to provide potential for rapid 
emergency federal support, when needed. Internationally, rapid 
drug-susceptibility test (DST) surveys and more sustained 
systematic capture of DST information are highlighted as 
areas to be addressed as part of a comprehensive response to 
XDR TB. Epidemiologic studies that make use of genotyping 
tools are recommended to elucidate XDR TB risk factors and 
transmission dynamics. Strategies also are needed to rapidly 
identify and respond to domestic and international XDR TB 
outbreaks.
Infection Control
Effective infection-control practices are critical to prevent 
the transmission and further spread of MDR and XDR TB 
in health-care settings and other congregate settings (e.g., 
correctional facilities and homeless shelters). CDC infection-
control guidelines were updated in December 2005 and should 
continue to be updated as needed (28). Further studies are 
needed to assess the effectiveness and feasibility of various 
infection-control strategies in different institutional settings. 
Testing workers for TB in various institutional settings is an 
important strategy for identifying workers infected with TB 
and detecting unsuspected transmission.
Clinical and Programmatic 
Interventions
Prevention and control of TB in the United States require a 
robust public health infrastructure that includes a workforce 
trained in TB prevention, diagnosis, treatment, and case 
management. Because some patients fail to recognize TB 
symptoms, health care often is not sought during early stages 
of disease. In addition, providers who are unfamiliar with signs 
and symptoms of TB and with diagnostic standards might not 
suspect TB, delaying the start of effective treatment. Access to 
comprehensive and affordable clinical TB services (i.e., pre-
ventive, diagnostic, and treatment/case management) should 
be provided to all persons with TB or those suspected to have 
TB. Health-care providers who screen persons for TB should 
use up-to-date diagnostic and treatment guidelines. More 
health-care workers are needed to provide directly observed 
therapy (DOT) for TB patients to ensure successful treat-
ment and help prevent development of disease attributable to 
drug-resistant TB.
Ethical and Legal Issues
Strict infection-control measures are necessary to prevent the 
spread of XDR TB. Patients with XDR TB might need to be 
placed in airborne infectious isolation while initial treatment 
response is monitored in order to prevent disease transmission 
to others. Guidance is needed regarding the ethical and legal 
issues involved in identifying and treating persons with XDR 
TB. The adequacy of current public health laws in the United 
States to address drug-resistant TB has not been studied com-
prehensively since 1993 (29). All states have laws to compel 
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isolation for persons with certain infectious diseases (including 
TB); however, these laws vary by state, and those for TB might 
be contingent on patient nonadherence and failure of voluntary 
measures. Public health authorities must balance the interests 
of the public with individual rights. Legal and ethical issues 
become even more complicated when persons have XDR TB 
because prolonged isolation might be necessary even when a 
patient is adherent. In addition, for some patients, no effec-
tive treatment is available that would allow for release from 
isolation on completion. Additional complexity also exists 
regarding non-U.S. citizens with infectious XDR TB who 
are scheduled to be repatriated to their native countries. U.S. 
public health officials might not be familiar with public health 
laws of other countries.
Communication and Education
As a result of TB incidence rates decreasing in the United 
States, health-care providers have received little training regard-
ing TB and consequently might not recognize the signs and 
symptoms of TB, which can lead to incorrect diagnosis and 
treatment, creation of drug resistance, and continued spread of 
TB in the community (30,31). Health-care providers should 
be educated about the signs and symptoms of TB, diagnostic 
methods, prevention, and treatment. In addition, education 
materials on MDR TB and XDR TB should be developed for 
the general public, populations at high-risk for TB on the basis 
of demographic and clinical characteristics, TB patients, TB 
prevention advocacy organizations, and policy makers, includ-
ing legislators. Education materials should include informa-
tional pamphlets, instructions for therapy, behaviors to prevent 
transmission, medical alerts, and descriptions of TB programs. 
Distribution of these materials should be coordinated across 
federal and state agencies and updated as necessary. Advocacy 
is critical to make the public aware of the importance of TB 
control to the public’s health, and to educate policy makers on 
the magnitude of the problems that will result if resources to 
state and local TB control programs continue to decline.
Research
The biomedical research challenges represented by drug-
resistant TB in the context of overall TB research activities 
have been described previously (10). Knowledge gaps remain 
regarding the genetics and growth characteristics of M. tuber-
culosis, the physiology and biochemistry of both the host and 
pathogen during infection, and the disease and genotypic 
and biologic markers that facilitate surveillance and indicate 
infection, disease, and drug resistance. Basic research needs to 
be supported to advance understanding of these issues and to 
help design new approaches to diagnosis and treatment. The 
emergence of drug-resistant TB illustrates the pressing need 
to develop new and effective drug regimens for the treatment 
of TB, including drugs to cure MDR TB and XDR TB and to 
prevent development of active disease among persons who are 
infected latently with drug-resistant M. tuberculosis. Because 
poor patient adherence to therapy is one factor that can lead to 
development of MDR TB and XDR TB, research of associated 
behavioral and social factors should be conducted to identify 
ways to improve patient adherence and treatment completion. 
New, rapid, and cost-effective diagnostic methods are needed, 
particularly for use in rural areas and developing countries. 
Ultimately, an effective vaccine is needed to eliminate TB.
Partnerships
To coordinate efforts to control XDR TB, existing partner-
ships must be strengthened, and new partnerships are needed 
between countries and within both the public and private 
sectors, including government and nongovernment organiza-
tions. Partnerships are necessary to focus existing resources 
on the most affected geographic areas, increase current public 
and private resources (both financial and human resources), 
coordinate the efforts (including research, education, labora-
tory, and programmatic), and raise awareness of the problem 
and consequences.
Cost Analysis
Comprehensive information is not available on the cost of 
treating and implementing programs and interventions to 
prevent XDR TB. Research on the cost of treating and prevent-
ing XDR TB is needed to calculate the cost-effectiveness and 
benefits of interventions and strategies to combat XDR TB.
Action Plan to Combat Extensively 
Drug-Resistant Tuberculosis
Diagnostic Laboratory
The laboratory plays a critical role in the diagnosis and 
management of drug-resistant TB. Test results must be avail-
able in a time frame that allows clinicians to make prompt 
patient management decisions. Many laboratory techniques 
used to confirm a TB diagnosis and to identify drug resistance 
were developed in the 1950s, 1960s, and 1970s. Substantial 
improvements have been made in culture techniques and 
in rapid methods in the past decade. However, these more 
accurate, rapid, and sophisticated methods have not been 
implemented widely, particularly in regions of the world where 
MDR TB and XDR TB are common and optimized algorithms 
for providing rapid point-of-care laboratory confirmation of 
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TB and detection of drug resistance have not been established. 
To combat the growing problem of resistance to TB drugs, 
the most current methods need to be applied to their fullest 
capacity while better diagnostic tests are developed. The needs 
of the TB laboratory must be addressed to make laboratory 
services for TB, MDR TB, and XDR TB more rapid, sensitive, 
reliable, and more responsive to the needs for patient manage-
ment, infection control, and TB control efforts. Although the 
challenges and potential solutions vary by setting, domestic 
and international TB laboratories face many of the same 
challenges.
Problem 1
Many clinicians, laboratorians, health-care professionals, 
public health officials, and policy makers do not possess up-
to-date knowledge of what constitutes appropriate laboratory 
capabilities and capacities or the appropriate use of tests to 
arrive at a prompt and accurate diagnosis of TB.
objective 1.1
Increase awareness of the need to develop necessary capac-
ity and capabilities for the laboratory diagnosis of TB. This 
includes proper use of diagnostic tests, prompt reporting of 
results, and appropriate interpretation of test results for estab-
lishing a definite diagnosis and for guiding management of TB 
(domestic and international).
Action Steps
1.1.1. Educate clinicians and public health officials about 
appropriate use of diagnostic services and tests, interpretation 
of laboratory test results, and the role of the diagnostic labora-
tory in monitoring treatment. Distribute current guidelines 
on TB diagnostic testing, drug-susceptibility testing, and 
laboratory services.
1.1.2. Conduct a survey of current practices and capabilities 
in private, hospital, commercial, and public TB laboratories 
to assess current methods and infrastructure used for direct 
detection of M. tuberculosis in patient specimens, and rapid 
testing for susceptibility to first- and second-line drugs.
1.1.3. Create or update self-assessment tools for private, 
hospital, commercial, and public laboratories to evaluate 
their practices in and knowledge of TB diagnosis and drug-
susceptibility testing to facilitate planning of continuous 
quality improvements. 
1.1.4. Educate policy makers, national health ministry 
officials, program officials, clinicians, laboratory managers, 
and laboratory directors about the role of prompt, reliable TB 
laboratory services in national and local health-care systems 
and public health programs.
1.1.5. Educate laboratorians, clinicians, and public health 
officials on the appropriate use of TB diagnostic laboratory 
services and the need for the integration of rapid tests into TB 
control programs to enhance patient care.
1.1.6. Identify and use resources available from regional juris-
dictions in resource-limited settings with expected increases 
in MDR TB and XDR TB cases to help improve capacity 
for drug-susceptibility testing and care of patients with drug-
resistant TB.
Lead federal agencies: U.S. Department of Health and 
Human Services (HHS) (CDC and NIH), USAID, and U.S. 
Department of Veterans Affairs (VA).
Suggested§ collaborators: U.S. Department of Defense 
(DoD), American Thoracic Society (ATS), Infectious Diseases 
Society of America (IDSA), Association of Public Health 
Laboratories (APHL), National TB Controllers Association 
(NTCA), Regional Training and Medical Consultation Centers 
(RTMCCs), WHO, national health ministry, academia, and 
public health and private laboratories.
Problem 2
Although the majority of domestic TB laboratories are pre-
pared to respond to MDR TB, many have limited capacity to 
respond to XDR TB.
objective 2.1
Ensure that required laboratory services are available to 
respond properly to XDR TB (domestic).
Action Steps
 2.1.1. Assess current domestic laboratory resources and 
capacity to create an integrated network of TB diagnostic 
resources necessary for a prompt and robust response to XDR 
TB anywhere in the United States.
2.1.2. Develop centers of excellence for TB diagnosis as 
part of a network of laboratories and information/specimen 
management systems that use standardized procedures for 
reporting within 2 days of identification of MDR and XDR 
M. tuberculosis from clinical specimens, tracking and referral 
for TB cases, and shipping of specimens.
2.1.3. Develop enhanced biosafety level 3 laboratories with 
appropriate facilities, trained staff, administrative controls, 
and monitoring programs to handle XDR M. tuberculosis 
strains safely.
2.1.4. Ensure second-line drug-susceptibility testing of iso-
lates from all patients identified with MDR TB.
2.1.5. Develop sufficient domestic laboratory capacity 
to accommodate rapid testing of M. tuberculosis strains in 
§ Organizations listed as suggested collaborators have not yet been approached 
to work on any recommended action steps.
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case of domestic and international TB outbreaks (surge 
capacity) and to provide comprehensive, ongoing coverage 
for surveillance.
2.1.6. Develop a laboratory component for a rapid XDR 
TB outbreak response plan and provide training to local, state, 
and federal responders.
2.1.7. Coordinate the CDC Universal TB Genotyping 
Program with TB genotyping programs of the European Union 
(EU) and other international partners to identify genotypes 
associated with XDR M. tuberculosis strains and develop an 
early warning system for the spread of XDR M. tuberculosis 
strains.
Lead federal agencies: HHS (CDC and NIH).
Suggested collaborators: APHL, NTCA, academia, and 
public health and private laboratories.
Problem 3
Current laboratory capacity is inadequate to identify, charac-
terize and track drug resistant M. tuberculosis strains in response 
to the XDR TB epidemic.
objective 3.1
Enhance laboratory capacity to support outbreak investiga-
tions and studies of XDR TB (domestic).
Action Steps
3.1.1. Provide support for MDR and XDR TB outbreak 
investigations through genotyping of M. tuberculosis isolates 
and rapid drug-susceptibility testing. 
3.1.2. Fully implement the CDC Universal TB Genotyping 
Program to track and monitor M. tuberculosis strain transmis-
sion in the United States.
3.1.3. Establish and support a national M. tuberculosis geno-
type and isolate archive to compare strains, epidemiologic data, 
and clinical outcomes from different geographic regions. 
3.1.4. Support efforts to determine genomic sequences of 
MDR and XDR M. tuberculosis strains to characterize resistance 
and aid in determining virulence mechanisms.
3.1.5. Provide overall technical laboratory assistance to 
investigate MDR TB and XDR TB outbreaks.
Lead federal agencies: HHS (CDC and NIH).
Suggested collaborators: NTCA, APHL, academia, and 
public health and private laboratories.
objective 3.2
Determine laboratory capacity needed for rapid XDR TB 
surveys in WHO-designated high-burden (defined by WHO as 
the 22 countries with the highest TB morbidity) and TB-focus 
countries¶ (international).
Action Steps
3.2.1. Assess capacities of national and international 
academic, private, commercial, and public laboratories to 
provide laboratory services needed to conduct rapid XDR 
TB surveys.
3.2.2. Provide immediate (emergency) surge capacity 
through U.S. laboratory resources to affected countries in 
response to MDR TB and XDR TB outbreaks. 
3.2.3. Develop a network of international quality-assured 
laboratories to conduct drug-susceptibility testing for XDR 
TB surveys.
3.2.4. Develop standardized methods for first- and sec-
ond-line drug-susceptibility testing to be used in XDR TB 
surveys.
3.2.5. Develop external quality assessment programs for 
surveys.
Lead federal agencies: HHS (CDC and NIH) and 
USAID.
Suggested collaborators: U.S. Department of State (DOS), 
DoD, WHO, APHL, American Society for Microbiology 
(ASM), NTCA, IUATLD, Royal Netherlands Tuberculosis 
Association (KNCV), Research Institute of Tuberculosis (RIT), 
public health and private laboratories, and academia.
Problem 4
The quality of and proficiency in TB laboratory diagnosis 
varies within the United States and internationally because a 
well-trained and stable laboratory workforce is not universally 
available.
objective 4.1
Provide training in conventional and new diagnostic meth-
ods for TB (domestic and international).
Action Steps
4.1.1. Provide training to private, commercial, and public 
health laboratory managers and supervisors in laboratory 
management and systems.
4.1.2. Provide training to TB laboratory personnel for con-
ventional and new diagnostic tests. 
4.1.3. Provide training in biosafety and safe manipulation 
of pathogenic mycobacteria.
4.1.4. Develop training materials for current, new, and 
emerging technologies for TB laboratory personnel.
¶ Countries that either 1) are WHO high-burden countries, 2) are countries 
from which the majority of foreign-born persons with TB in the United States 
originate (e.g. Mexico, the Philippines, and Vietnam), 3) have high HIV/TB 
prevalence, or 4) have a high prevalence of MDR TB.
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4.1.5. Provide opportunities for exchange of person-
nel between laboratories in resource-limited settings to 
share knowledge about successful approaches to laboratory 
diagnosis.
4.1.6. Develop programs to assist laboratory managers in 
maintaining proficiency in TB laboratory services or to obtain 
services from referral laboratories.
4.1.7. Explore opportunities to integrate TB laboratory 
personnel into the general clinical laboratory workforce to 
strengthen overall human resource capacity at the local, district, 
and provincial levels.
4.1.8. Develop programs to inform and educate health-care 
providers about new tests for TB, their potential usefulness in 
establishing a diagnosis or monitoring therapy, and their cost/
benefit over existing approaches. 
4.1.9. Evaluate the effectiveness of newly developed training 
activities and programs to build laboratory capacity.
Lead federal agencies: HHS (CDC), and USAID.
Suggested collaborators: DoD, APHL, NTCA, National 
Laboratory Training Network (NLTN), STOP TB USA, 
WHO, IUATLD, Clinical Laboratory Standards Institute 
(CLSI), the Global Fund, and the World Bank.
Problem 5
TB laboratory services at certain local public health labo-
ratories are limited and might depend on access to networks 
of other public and private laboratories with better diagnostic 
capabilities, which often leads to substantial delays in diagnosis 
and treatment of TB.
objective 5.1
Develop a systems approach to improving TB laboratory 
services at the local level (domestic).
Action Steps
5.1.1. Assess available TB laboratory services in a jurisdiction 
to determine the status and capacity of services and to identify 
unmet needs, obstacles to obtaining services, and opportunities 
for improvement.
5.1.2. Assess the actual costs of providing TB laboratory 
services through existing programs and develop a business plan 
for providing these services through an integrated system of 
laboratory services in the United States.
5.1.3. Develop a strategic plan for implementing and main-
taining a systems approach to TB laboratory services.
5.1.4. Develop outcome measures to assess performance 
of and improvements in laboratory services and overall TB 
control programs.
Lead federal agencies: HHS (CDC).
Suggested collaborators: APHL, NTCA, state and local 
TB programs, academia, and public health and private 
laboratories.
objective 5.2
Develop integrated TB laboratory systems in high-
burden countries and countries with limited resources 
(international).
Action Steps
5.2.1. Inventory and assess available academic, private, 
commercial and public TB laboratory service providers to 
determine each country’s domestic capacity to provide services 
for TB program and patient care activities.
5.2.2. Develop a network of public and private TB laborato-
ries that use standardized and quality controlled methods for 
information and specimen management to meet the needs of 
the local and national TB treatment and control programs. 
5.2.3. Provide training to develop national expertise in TB 
diagnostic laboratory services, patient care and TB control 
activities through engagement of national academic and clini-
cal research programs. 
5.2.4. Develop program-specific plans and phased approaches 
to improving laboratory services in national, country-level 
regional and peripheral (local) laboratories.
5.2.5. Develop local, district, regional, and national laborato-
ries, including referral laboratories, that provide reliable services 
through conventional and rapid methods for TB diagnosis, 
drug-susceptibility testing and patient care.
5.2.6. Develop or ensure access to effective external quality 
assessment programs for laboratory services (e.g., acid fast bacil-
lus [AFB]–smear microscopy, culture, and drug-susceptibility 
testing) provided at each level.
5.2.7. Support development of laboratory standards and 
accreditation programs with an emphasis on culture and 
drug-susceptibility testing to facilitate assessment and quality 
improvement of national and regional laboratories. 
5.2.8. Explore options to increase TB laboratory capacity as 
part of efforts to improve general diagnostic laboratory service 
capacity and overall health sector reform.
5.2.9. Identify interim laboratory support services until local 
and regional capacity is developed.
5.2.10. Support research to develop inexpensive, high-quality 
diagnostic tools that can be used in resource-limited settings.
Lead federal agencies: HHS (CDC and NIH), and 
USAID.
Suggested collaborators: DoD, DOS, NTCA, APHL, ASM, 
WHO, and IUATLD.
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Problem 6
Culture-based laboratory tests to identify persons with 
XDR TB are slow, lack sensitivity, and have poor reliability, 
resulting in delayed diagnosis, treatment, and public health 
control efforts. 
objective 6.1
Improve the ability of TB laboratories to identify and report 
drug-resistant M. tuberculosis (domestic).
Action Steps
6.1.1. Develop local, district, state, regional, or referral labo-
ratories that are able to rapidly identify M. tuberculosis bacteria 
in patient specimens and determine drug susceptibilities to 
first- and second-line agents using state-of-the-art conventional 
or rapid methods.
6.1.2. Encourage the use of state-of-the-art rapid tests for 
detection of M. tuberculosis and drug-susceptibility testing 
through focused laboratory funding.
6.1.3. Develop a bank of M. tuberculosis isolates for use in 
proficiency testing and research. 
6.1.4. Implement proficiency testing programs and external 
quality assessment programs for new drug-susceptibility tests 
and rapid methods.
6.1.5. Assist laboratories in developing and implementing 
an integrated information management system for inventory, 
specimen tracking, reporting, and information sharing.
6.1.6. Identify interim laboratory support services until local 
and regional capacities are developed.
Lead federal agencies: HHS (CDC and NIH).
Suggested collaborators: APHL and NTCA.
Problem 7
The lack of guidelines for the use of conventional and 
rapid culture-based or molecular methods for detection of M. 
tuberculosis and drug resistance impedes the widespread use 
of these tests.
objective 7.1
Develop consensus guidelines to address TB laboratory test-
ing in the United States, in high-burden and in focus countries 
(domestic and international). 
Action Steps
7.1.1. Develop consensus guidelines for culture, drug-suscep-
tibility, and rapid diagnostic testing to be used in local, district, 
state, national, and country-level regional laboratories.
7.1.2. Develop consensus guidelines for the use of rapid 
methods (e.g., nucleic acid amplification tests) to detect M. 
tuberculosis directly from patient specimens.
7.1.3. Develop consensus guidelines for the use of rapid, 
molecular methods for drug-susceptibility testing.
7.1.4. Develop consensus guidelines for culture-based meth-
ods to determine resistance to second-line TB drugs.
7.1.5. Conduct operational and implementation research to 
develop guidelines for optimal algorithms for TB laboratory 
testing, specimen referral, and reporting.
Lead federal agencies: HHS (CDC and NIH) and 
USAID.
Suggested collaborators: APHL, ATS, IDSA, CLSI, WHO, 
IUATLD, and academia.
Problem 8
The current process for evaluating newly developed diagnos-
tic tests can be time consuming and delay implementation for 
routine clinical use.
objective 8.1
Develop strategies for expedited evaluation and implementa-
tion of new rapid methods for laboratory confirmation of TB 
and identification of drug-resistance patterns (domestic and 
international).
Action Steps
8.1.1. Evaluate and deploy methods to optimize AFB sputum 
smear microscopy.
8.1.2. Evaluate and deploy sensitive and rapid molecular tests 
to detect M. tuberculosis directly in sputum specimens.
8.1.3. Evaluate and deploy rapid culture methods for isolat-
ing M. tuberculosis.
8.1.4. Evaluate and deploy rapid culture-based or molecular 
drug-susceptibility testing methods.
8.1.5. Develop methods to validate genotypic indicators of 
resistance through phenotypic susceptibility results and the 
patient’s response to treatment.
8.1.6. Develop consensus methods and guidelines for the 
introduction and use of new diagnostic methods, including 
in resource-limited settings.
8.1.7. Provide access to well-characterized drug-susceptible 
and drug resistant-strains of M. tuberculosis for identification 
of drug-resistance markers.
8.1.8. Expand the genomic characterization of drug-resistant 
M. tuberculosis strains to identify new markers of resistance to 
second-line drugs.
8.1.9. Evaluate the cost effectiveness and appropriate use of 
available and new rapid methods and approaches to identify 
of MDR/XDR M. tuberculosis.
8.1.10. Determine and promote the most effective point-
of-care drug-susceptibility testing methods and diagnostic 
algorithms and strategies, including molecular testing at the 
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local level followed by transport of positive specimens to full-
service laboratories for further evaluation.
8.1.11. Provide access to or conduct clinical trials in partner-
ship with high-burden countries to validate new microbiologic 
drug-susceptibility tests as part of local diagnostic procedures/
algorithms. 
8.1.12. Discuss with FDA criteria that will be required for 
approval of new tests for identification of drug-resistant TB 
and to perform rapid drug-susceptibility testing.
Lead federal agencies: HHS (CDC, FDA, and NIH), and 
USAID.
Suggested collaborators: DoD, Foundation for Innovative 
New Diagnostics (FIND), WHO Special Programme for 
Research and Training in Tropical Diseases [TDR]), academia, 
public health laboratories, and IUATLD.
Problem 9
The laboratory confirmation of TB in HIV-infected persons 
is difficult and time consuming because of the need for highly 
sensitive, sophisticated and technically challenging diagnostic 
tests that are not universally available in all settings with a high 
burden of HIV and TB.
objective 9.1
Improve laboratory confirmation of TB, MDR TB, and XDR 
TB in HIV-infected persons (domestic and international).
Action Steps
9.1.1. Strengthen TB laboratory capacity to detect AFB-
smear negative TB through support of global efforts to build 
culture capacity in TB laboratories and develop methods to 
increase sensitivity of AFB-smear microscopy.
9.1.2. Develop and evaluate effective laboratory testing algo-
rithms and specimen referral systems to prioritize specimens 
from HIV-infected persons appropriately.
9.1.3. Integrate TB laboratory capacity building with HIV 
laboratory capacity building.
9.1.4. Evaluate and deploy the use of sensitive and rapid 
molecular tests to detect M. tuberculosis directly in sputum and 
other clinical specimens from HIV-positive persons. 
Lead federal agencies: HHS (CDC and NIH), and 
USAID.
Suggested collaborators: DOS, DoD, FIND, WHO 
(TDR), ASM, APHL, academia, IUATLD, and public health 
laboratories.
Problem 10
Current technical assistance for laboratory capacity building 
is sporadic and not well coordinated or integrated often leading 
to unclear and inconsistent guidance. 
objective 10.1
Develop consistent and well-coordinated approaches to 
technical assistance and consultation for TB laboratories in 
high-burden and focus countries (international).
Action Steps
10.1.1. Develop technical assistance approaches and practices 
that are coordinated, consistent, and compatible with the efforts 
of international partners such as WHO and IUATLD.
10.1.2. Establish a cadre of well-trained consultants to help 
guide coordinated approaches to building TB laboratory capac-
ity in high-burden and focus countries.
10.1.3. Contribute to the coordinated development of stan-
dardized checklists and templates for laboratory evaluation and 
training materials for laboratory capacity building efforts.
10.1.4. Contribute to the coordinated development of 
external quality assessment guidance and documents for 
microscopic and culture identification of M. tuberculosis and 
drug-susceptibility testing.
10.1.5. Contribute to the coordinated development of widely 
compatible laboratory information systems to facilitate transfer 
of information within and between TB control programs.
10.1.6. Promote expansion of the Supranational Laboratory 
Network through inclusion of reference laboratories that can 
assist in capacity building and external quality assessment.
10.1.7. Promote expansion of the Supranational Laboratory 
Network proficiency testing to include second-line drug-
susceptibility testing.
10.1.8. Promote and coordinate partnering of public health 
laboratories in the United States with public health laboratories 
in high-burden and focus countries.
Lead federal agencies: HHS (CDC and NIH), and 
USAID.
Suggested collaborators: DoD, DOS, NTCA, APHL, ASM, 
WHO, and IUATLD.
Problem 11
Providing technical assistance is logistically difficult.
objective 11.1
Establish international regional centers of excellence to 
facilitate implementation of technical assistance provided 
by the United States to TB endemic or TB-focus countries 
(international).
Action Steps
11.1.1. Build expertise for technical assistance to TB 
laboratories at selected centers of excellence in high-burden 
countries.
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11.1.2. Provide opportunities for peer-to-peer training 
and exchange of laboratory personnel in resource limited 
settings.
11.1.3. Assist centers of excellence in developing training 
programs for program staff, laboratory managers and bench 
workers on establishing methods for external quality assessment 
processes through site visits and monitoring. 
11.1.4. Assist centers of excellence in establishing reference 
laboratory services for identification of M. tuberculosis and 
susceptibility testing for first- and second-line drugs that would 
qualify them as Supranational Reference Laboratories and that 
could be made available to partner programs. 
Lead federal agencies: HHS (CDC and NIH) and USAID.
Suggested collaborators: DOS, DoD, WHO, IUATLD, 
APHL, ASM, KNCV, RIT, academia, and public health 
laboratories.
Problem 12
Resources available to TB laboratories are often inadequate 
for building and maintaining the necessary infrastructure and 
competencies to provide consistently high-quality diagnostic 
services.
objective 12.1
Mobilize resources and support international efforts 
to strengthen and sustain TB laboratory capacity 
(international).
Action Steps
12.1.1. Identify funding opportunities through the 
President’s Emergency Plan for AIDS Relief, USAID, and 
the Global Fund to contribute to strengthening international 
laboratory efforts.
12.1.2. Support global efforts (e.g., WHO’s strategic 
approach to the strengthening of laboratory services for TB 
control).
12.1.3. Support the Stop TB Partnership’s Global Laboratory 
Initiative and the DOTS (directly observed therapy, short 
course) Expansion Working Group.
Lead federal agencies: USAID and HHS (CDC).
Suggested collaborators: DOS, WHO, the Bill & Melinda 
Gates Foundation, APHL, and the American Lung Association 
(ALA).
Problem 13
The role of public and private TB laboratories in the diag-
nosis of persons latently infected with XDR M. tuberculosis 
has not been defined clearly.
objective 13.1
Develop laboratory services to identify persons with 
drug-resistant latent M. tuberculosis infection (DR LTBI) 
(domestic).
Action Steps
13.1.1. Assess the capacity of public and private TB laborato-
ries to support DR LTBI diagnostic testing by determining the 
status and capacity of currently available services and identify-
ing gaps, obstacles and opportunities for improvement.
13.1.2. Develop materials and programs to train laboratory 
personnel in DR LTBI diagnostic testing.
13.1.3. Develop consensus laboratory guidelines for DR 
LTBI testing methods.
13.1.4. Conduct operational research to optimize testing 
and referral algorithms.
13.1.5. Develop proficiency testing and external quality 
assessment modules for DR LTBI diagnosis.
13.1.6. Conduct Phase 4 clinical studies of new technologies 
for DR LTBI diagnosis and management.
Lead federal agencies: HHS (CDC, FDA, NIH).
Suggested collaborators: DoD, NTCA, APHL, CLSI, ATS, 
and IDSA.
Problem 14
International laboratory services used by physicians under 
provisions of the United States Immigration and Nationality 
Act often are not equipped to the standards of U.S. TB pro-
grams and might not be able to reliably identify persons with 
drug-susceptible or MDR TB and XDR TB. 
objective 14.1
Evaluate and improve the ability of international laboratories 
employed to identify M. tuberculosis and perform drug-suscep-
tibility testing for potential U.S. immigrants (international).
Action Steps
14.1.1. Determine which high-burden country issues the 
largest number of immigrant visas and identify the top 20 
immigrant visa processing posts.
14.1.2. Identify and assess the diagnostic capabilities of 
laboratories used by physicians affiliated with these visa pro-
cessing posts.
14.1.3. Assure that evaluations and improvements in TB 
laboratory services used for medical evaluation of visa appli-
cants are coordinated with overall efforts to improve national 
TB programs.
14.1.4. Provide training on the basis of U.S. government 
policies for the medical examination of aliens (available at 
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http://www.cdc.gov/ncidod/dq/health.htm) to TB laboratories 
used by examining physicians to facilitate improvement of 
laboratory proficiency for identification of M. tuberculosis and 
diagnosis of drug-susceptible and drug-resistant TB.
14.1.5. Provide oversight, proficiency testing, and consulta-
tion to ensure adequate TB diagnostic and drug-susceptibility 
testing capability are available for visa applicants in interna-
tional screening laboratories.
Lead federal agencies: U.S. Department of Homeland 
Security (DHS), and HHS (CDC).
Suggested collaborators: DOS and the International 
Organization for Migration.
Problem 15
Limited capacity exists for the evaluation of new TB diag-
nostic tests (see Problem 54).
objective 15.1
Evaluate new methods to provide rapid and reliable labora-
tory confirmation of TB and identify patterns of drug resistance 
(domestic).
Action Steps
15.1.1. Contribute to the development and clinical evalua-
tion of rapid and simple methods to identify and characterize 
MDR/XDR strains of M. tuberculosis.
15.1.2. Facilitate the development of improved diagnostic 
tests for rapid diagnosis of TB disease in persons with either 
compromised or intact immune systems.
15.1.3. Evaluate the specificity and sensitivity of candidate 
tests to rapidly diagnose and identify resistant M. tuberculosis 
strains in field settings.
15.1.4. Provide training in implementation research and 
field evaluations, and build clinical trial capacity to evaluate 
new laboratory tests.
Lead federal agencies: HHS (CDC, FDA, and NIH), and 
USAID.
Suggested collaborators: DoD, FIND, and academia.
Surveillance, Epidemiology, and 
outbreak Investigations
Identifying outbreaks of XDR TB to prevent further trans-
mission requires a rapid, accurate, and adaptable surveillance 
system and coordinated response strategies. In the United 
States, individual states require reporting of TB cases by 
health-care providers and facilities to public health authorities. 
By mutual agreement, state health authorities report TB cases 
to CDC. Substantial delays can occur in reporting to CDC 
because many states report on a quarterly basis or at the end of 
the year. Key domestic surveillance needs include immediate 
case reporting, accurate and complete reporting of second-line 
drug susceptibility and genotyping results, and active case 
finding among contacts and other high risk groups. Central 
notification of MDR and XDR TB is essential to identify cross-
jurisdictional issues and to outline specific areas that should 
be targeted for rapid emergency (federal) support. Improved, 
unambiguous technical guidance (including outcome stan-
dards) is needed for collection, reporting, and data-quality 
procedures at the local, state, and federal levels. Internationally, 
areas that require increased attention and improvement include 
capacity for rapid DST surveys and more sustained, systematic 
capture of DST information. Epidemiologic studies, includ-
ing genetic analyses of host and pathogen, are recommended 
to elucidate risk factors for acquiring XDR TB, transmission 
dynamics and determinants of host survival.
Problem 16
No requirement exists for rapid reporting of TB cases to the 
National TB Surveillance System (NTSS), and many state and 
city TB programs report to NTSS only quarterly or at the end 
of the year, thus substantially limiting the ability to identify 
rapidly and respond promptly to outbreaks of MDR TB and 
XDR TB.
objective 16.1
Develop a plan for reporting known or suspect MDR TB and 
XDR TB cases to the NTSS with no time lag (domestic).
Action Steps
16.1.1. Convene a working group of stakeholders (CDC, 
NTCA, local and state TB control programs, laboratorians) 
to develop an integrated plan for immediate notification of 
MDR TB and XDR TB cases.
16.1.2. Establish clear requirements and methods for report-
ing of MDR TB and XDR TB cases from local clinics to labo-
ratories, hospitals, and other partners who might diagnose TB 
in patients to the state TB program and to NTSS.
16.1.3. Develop standard reports of aggregated XDR TB 
case data within the NTSS to provide to local and state TB 
programs.
16.1.4. Define mechanisms to provide feedback to state and 
local programs and partners regarding missing data, incomplete 
diagnostic information, and needed follow-up information.
16.1.5. Develop procedures and data requirements that allow 
public health agencies to identify and address large-scale and 
interjurisdictional issues and to request rapid mobilization of 
a federal response in case of emergencies.
16.1.6. Develop and maintain a national registry for MDR 
TB and XDR TB outside the NTSS that is linked to the 
national genotyping database or contains genotyping results 
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from the state TB programs. The registry should include per-
sons with reported cases and with nonreportable (noncounted) 
cases of MDR TB and XDR TB and persons with cases of TB 
identified by clinical diagnosis alone who are known contacts 
to culture-confirmed MDR TB or XDR TB.
16.1.7. Develop required data elements for the national 
registry that include relevant clinical data, information about 
primary or secondary MDR TB and XDR TB cases, detailed 
history of prior and current drug treatment and susceptibility 
test results incorporating expanded second-line drug panels.
16.1.8. Develop web-based access to the national registry for 
state and local health departments, diagnostic laboratories and 
relevant public health officials with appropriate safeguards to 
protect sensitive information and personal identifiers.
Lead federal agencies: HHS (CDC and Health Resources and 
Services Administration [HRSA]), Bureau of Prisons (BOP), 
and DHS (Immigration and Customs Enforcement [ICE]).
Suggested collaborators: state TB program directors, TB 
controllers, TB program surveillance coordinators, state bor-
der health offices, NTCA, and private and state public health 
laboratories.
Problem 17
Data reported to the NTSS, including data for XDR 
TB cases, often are not fully validated for accuracy and 
completeness.
objective 17.1
Develop a plan to determine and assure completeness and 
accuracy of all reported TB data, including those for XDR TB 
cases (domestic).
Action Steps
17.1.1. Review the data currently required for reports of 
completeness of information collection for each variable 
that is requested of state TB programs by NTSS and expand 
these reports to reflect critical information pertinent to XDR 
TB (e.g., initial and final DST results and initial treatment 
strategy).
17.1.2. Conduct site visits or standardized surveys to review 
current surveillance procedures for state and local health 
departments and identify opportunities for improvement.
17.1.3. Develop a standardized plan to validate Report of 
Verified Case of TB (RVCT) data among persons with cases 
of MDR TB and XDR TB, using medical and clinic record 
review at the local reporting area.
Lead federal agencies: HHS (CDC).
Suggested collaborators: state TB program directors, TB 
controllers and surveillance coordinators, NTCA, private com-
mercial laboratories, and state public health laboratories.
Problem 18
For 66% of MDR TB cases reported to the NTSS during 
2000–2006, DST results were incomplete and not sufficient to 
estimate the proportion of XDR TB among MDR cases, and 
20% of MDR TB cases lacked information about susceptibility 
to any of the second-line drugs.**
objective 18.1
Increase testing for and reporting of DST results to the 
NTSS (domestic).
Action Steps
18.1.1. Analyze annually the completeness of second-line 
drug-susceptibility testing for all MDR M. tuberculosis isolates 
by state and contact each state with less than 100% complete-
ness for second-line drug-susceptibility testing.
18.1.2. Determine whether incomplete DST data are the 
result of incomplete testing or incomplete reporting.
18.1.3. Establish a notification system through which 
CDC’s Division of Tuberculosis Elimination (DTBE) program 
consultants are alerted to visit state TB programs to discuss 
improvements in drug-susceptibility testing and reporting, 
including review of instructions for reporting DST results to 
the current RVCT and the newly-formed MDR TB and XDR 
TB national registry.
18.1.4. Develop a process through which routine requests 
for missing DST results for MDR TB cases are requested from 
state TB programs.
18.1.5. Develop programs to ensure that personnel at the 
local and state TB programs are adequately trained in necessary 
procedures and reporting requirements for drug-susceptibility 
testing.
Lead federal agencies: HHS (CDC).
Suggested collaborators: state TB program directors, TB 
controllers and surveillance coordinators, NTCA, private and 
state public health laboratories, and APHL.
Problem 19
Laboratory reporting of DST results to the state health 
department is not standardized across the United States.
objective 19.1
Standardize laboratory reporting to the state health depart-
ments by state and private laboratories throughout the United 
States (domestic).
 ** Percentages are based on reported drug-susceptibility test results in the 2006 
NTSS database. Adequate testing for XDR TB uses the WHO definition: TB 
that is resistant 1) to isoniazid and rifampin and 2) to any fluoroquinolone 
and at least one of three injectable second-line drugs (amikacin, kanamycin, 
or capreomycin).
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Action Steps
19.1.1. Convene a working group of TB program and labo-
ratory experts to develop a standardized format for laboratory 
reporting. Disseminate the recommended reporting method 
to TB programs and public health and private laboratories via 
their professional associations.
Lead federal agencies: HHS (CDC).
Suggested collaborators: state TB program directors, TB 
controllers and surveillance coordinators, NTCA, private and 
state public health laboratories, and APHL.
Problem 20
Active case-finding procedures for XDR TB and MDR TB 
at the state and local level are not standardized.
objective 20.1
Develop standard guidelines for state and local TB programs 
to ensure prompt identification and reporting of newly diag-
nosed cases of XDR TB and MDR TB (domestic).
Action Steps
20.1.1. Review case-finding and reporting procedures among 
local and state TB programs and evaluate their effectiveness 
and promptness.
20.1.2. Convene a working group of state TB program 
personnel to develop standardized guidelines for prompt case 
finding and reporting at the state and local level.
20.1.3. Develop guidelines for contact tracing during inves-
tigations of XDR TB patients (see Problem 26) that facilitate 
rapid identification of close contacts at highest risk for active 
disease.
Lead federal agencies: HHS (CDC), BOP, and DHS 
(ICE).
Suggested collaborators: state TB program directors, TB 
controllers and surveillance coordinators, NTCA, and private 
and state public health laboratories.
Problem 21
Certain groups of foreign-born persons, persons living in 
correctional facilities, and marginalized persons (i.e., persons 
who are isolated, excluded, or alienated from mainstream 
society) are at increased risk for TB and XDR TB.
objective 21.1
Enhance surveillance for MDR TB and XDR TB among 
risk groups of foreign-born persons, incarcerated persons, and 
other marginalized at-risk persons (domestic).
Action Steps
21.1.1. Develop procedures for enhanced TB disease surveil-
lance among inmates who are either foreign-born or belong to 
other groups with high rates of tuberculosis who have resided 
outside the United States or Canada for >6 months before 
their incarceration.
21.1.2. Develop guidelines for medical follow-up and referral 
of persons with abnormal chest radiographs for microbiologic 
diagnosis and treatment for TB during incarceration and after 
release.
21.1.3. Develop recommendations and guidelines for diag-
nosis, treatment, and medical management of incoming and 
existing inmates, transfers, and those who are released from 
prison.
21.1.4. Contribute to the establishment of partner programs 
for evaluation of routine intake processes and surveillance used 
by all types of correctional facilities and detention centers to 
facilitate implementation of the recommended action plans 
for identification and management of XDR TB.
Lead federal agencies: HHS (CDC), DHS (ICE and 
Customs and Border Protection [CBP]), and U.S. Department 
of Justice (DOJ) (BOP and USMS).
Suggested collaborators: state TB program directors, TB 
controllers and surveillance coordinators, NTCA, correctional 
health systems administrators and providers, and private and 
state public health laboratories.
Problem 22
Reporting criteria for national surveillance of TB currently 
exclude patients who are expected to be in the United States 
for <90 days and persons who cross the border frequently.
objective 22.1
Develop a mechanism at the federal level for recording and 
tracking of cases that are not officially included in national case 
counts (see Problem 16, action step 16.1.6) (domestic).
Action Steps
22.1.1. Establish a mechanism to report all TB cases in 
persons identified or treated in the United States who do not 
meet current reporting criteria for national surveillance (e.g., 
are not residents).
Lead federal agencies: (CDC and HRSA), DHS (ICE and 
CBP), and DOJ (BOP and USMS).
Suggested collaborators: state TB program directors, TB 
controllers and surveillance coordinators, state border health 
offices, NTCA, private, and state public health and hospital 
laboratories.
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Problem 23
In areas where XDR TB has been identified, the actual 
prevalence of resistance to first- and second-line drugs among 
TB cases is unknown.
objective 23.1
Estimate the prevalence of resistance to first- and second-line 
drugs among reported TB cases (international).
Action Steps
23.1.1. Conduct rapid drug-susceptibility surveys in areas 
where XDR TB has been identified.
23.1.2. Contribute to the development of international 
guidelines for standardized drug-susceptibility testing.
23.1.3. In collaboration with international partners, identify 
barriers to conducting drug-susceptibility testing and develop 
solutions to overcome these obstacles.
Lead federal agencies: HHS (CDC) and USAID.
Suggested collaborators: WHO, national health ministries, 
supranational reference laboratories, and IUATLD.
objective 23.2
Increase capacity to perform sustained drug-susceptibility 
testing on a routine basis and develop procedures and meth-
ods for systematic recording and tracking of data trends 
(international).
Action Steps
23.2.1. Develop national TB registries/surveillance systems 
that include DST results for each case.
23.2.2. Identify barriers to increasing capacity for drug-
susceptibility testing in resource-limited settings.
23.2.3. Increase laboratory capacity (see Problems 2, 3, 6, 
and 10).
23.2.4. Support clinical evaluation of novel rapid diagnostic 
tools and drug-susceptibility testing (see Problem 15).
Lead federal agencies: HHS (CDC) and USAID.
Suggested collaborators: WHO, national health ministries, 
APHL, and IUATLD.
Problem 24
The risk factors for and transmission dynamics of XDR 
TB in domestic and international settings are not completely 
understood.
objective 24.1
Determine global epidemiologic profiles and transmission 
dynamics of XDR TB in different geographic areas (domestic 
and international).
Action Steps
24.1.1. Conduct retrospective analyses of epidemiologic and 
genotyping data and linkages from existing XDR TB contact 
investigations and national genotyping databases.
24.1.2. Develop an approach for regular and systematic 
analysis of national genotyping data for XDR M. tuberculosis 
isolates.
24.1.3. Compare drug-resistance profiles and treatment 
histories among previously treated and newly diagnosed cases 
of drug-resistant TB and establish the proportion of XDR TB 
and MDR TB among these different patient groups.
24.1.4. Determine and report the relationship between viru-
lence factors identified for XDR M. tuberculosis and clinical 
disease manifestation of XDR TB (see Problem 52).
Lead federal agencies: HHS (CDC and NIH).
Suggested collaborators: state and local health departments, 
WHO, and national health ministries.
objective 24.2
Determine the proportion of XDR TB cases occurring 
among newly diagnosed and previously treated TB cases, and 
how this distribution varies by geographic region and within 
separate patient groups (domestic).
Action Steps
24.2.1. Conduct retrospective analyses of patterns of drug 
resistance and treatment histories for MDR TB and XDR TB 
cases from national surveillance system and cohort studies to 
identify risk factors for the development of secondary XDR 
TB.
24.2.2. Design multisite prospective studies to evaluate the 
impact of treatment strategies on the development and clinical 
outcomes for MDR TB and XDR TB patients on the basis of 
the results from retrospective analyses of relevant cohorts.
Lead federal agencies: HHS (CDC and NIH).
Suggested collaborators: state and local health departments, 
public health laboratories, private physicians, and academia.
objective 24.3
Describe transmission dynamics of MDR TB and XDR TB 
(domestic).
Action Steps
24.3.1. Analyze data from existing XDR TB contact investi-
gations and national genotyping data to identify factors driving 
the transmission of XDR TB in high and low TB incidence 
settings.
Lead federal agencies: HHS (CDC).
Suggested collaborators: state and local health departments.
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objective 24.4
Identify strains of XDR M. tuberculosis that are associated 
with increased transmissibility and virulence (domestic).
Action Steps
24.4.1. Conduct retrospective in-depth analyses of XDR 
TB cases for which linked clinical and M. tuberculosis strain 
genotyping information is available from national and other 
genotyping databases.
24.4.2. Develop protocols to follow these cases prospec-
tively and to add new cases to the cohort as they receive a 
diagnosis.
Lead federal agencies: HHS (CDC and NIH).
Suggested collaborators: state and local health departments, 
private and state public health laboratories, and APHL.
Problem 25
The survival rates among patients with TB that is resistant 
to first- and second-line therapeutics have not been adequately 
analyzed, and host/pathogen determinants of survival, includ-
ing the effect of co-morbidities, remain to be elucidated.
objective 25.1
Conduct studies to identify determinants of survival among 
MDR TB and XDR TB patients, and how survival varies by 
host and pathogen factors (domestic and international). 
Action Steps
25.1.1. Conduct retrospective analyses of national surveil-
lance data and other cohort studies to understand differences 
in and factors affecting survival among drug-susceptible and 
MDR TB and XDR TB patients.
25.1.2. Design multisite prospective studies of treatment 
practices and other factors that affect clinical outcomes for 
MDR TB and XDR TB patient on the basis of results from 
retrospective analyses in relevant cohorts.
Lead federal agencies: HHS (CDC and NIH) and USAID.
Suggested collaborators: DOS, state and local health depart-
ments, WHO, national health ministries, IUATLD, and 
academia.
Problem 26
Methods for detecting and documenting outbreaks of XDR 
TB both domestically and internationally are not currently 
optimized to allow a rapid response.
objective 26.1
Improve speed and accuracy of detection and investigation 
of MDR TB and XDR TB outbreaks in the United States 
to include rapid identification of risk factors for transmis-
sion and recommendations to interrupt further transmission 
(domestic).
Action Steps
26.1.1. Develop systems to use surveillance data in combi-
nation with strain genotyping for detection of MDR TB and 
XDR TB transmission events immediately as they become 
known to the local TB clinic or local provider.
26.1.2. Establish rapid and enhanced procedures for report-
ing of MDR TB and XDR TB cases to CDC by TB controllers 
and for identification and reporting of MDR TB and XDR 
TB clusters on the basis of monthly review of the genotyping 
database combined with the RVCT.
26.1.3. Expand processes available for triggering rapid 
investigation of TB clusters to include MDR TB and XDR TB 
through generation of MDR TB and XDR TB cluster reports 
to be shared among DTBE senior staff; establish procedures 
to alert the respective State TB Controllers and other relevant 
interjurisdictional areas and rapidly review available data to 
prioritize on-site responses.
26.1.4. Establish plans to initiate case contact investigations 
through state TB programs and establish procedures for report-
ing of aggregate data (numbers of cases, contacts, numbers 
tested, numbers treated for LTBI and numbers completing 
treatment) to DTBE for each contact investigation of an MDR 
TB and XDR TB patient.
26.1.5. Develop policies to ensure complete evaluation and 
follow-up for all close and high-priority contacts of MDR 
TB AND XDR TB cases if state or local health departments 
are unable to complete contact investigations without outside 
assistance.
26.1.6. Develop a federal plan with clearly defined roles 
within and among federal agencies to allow identification of 
interjurisdictional issues in the tracing and management of 
MDR TB and XDR TB cases to ensure rapid and coordinated 
management of patients that travel to and from, or within the 
United States.
Lead federal agencies: HHS (CDC) and DHS.
Suggested collaborators: state and local health departments 
and state public health laboratories.
objective 26.2
Provide assistance to WHO and countries outside the 
United States for rapid investigation of MDR TB and XDR 
TB outbreaks, including the identification of risk factors for 
transmission and the recommendation of responses to interrupt 
transmission and contain outbreaks (international).
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Action Steps
26.2.1. Establish procedures for prioritization of invited 
responses to assist in the investigation of MDR TB and 
XDR TB cases by host countries on the basis of available 
information.
26.2.2. Formulate goals and objectives for the outbreak 
response team that are consistent with the specific request for 
assistance by the host country.
26.2.3. Establish a rapid response team to investigate the 
outbreak and define procedures for communication between 
the host country’s ministry of health, the CDC Director’s 
Emergency Operation Center, DTBE, and WHO that include 
consideration for potential large-scale interjurisdictional issues 
that will require rapid resolution.
Lead federal agencies: HHS (CDC) and USAID.
Suggested collaborators: DOS, WHO, and national health 
ministries.
Infection Control
Because TB is spread by the airborne route, anyone who 
breathes air containing viable tubercle bacilli is at risk for 
acquiring M. tuberculosis infection. This includes persons caring 
for and exposed to infectious TB patients, especially patients 
without an established diagnosis. To prevent the spread of 
disease and maintain the best possible care for patients, special 
infection-control practices and procedures must be available.
Effective infection control depends on early detection and 
diagnosis of TB disease, prompt initiation of effective therapy, 
and airborne infection isolation to prevent further disease 
transmission. Each institutional setting that might house 
persons with undiagnosed TB disease or in which TB patients 
are treated should have infection-control programs available 
that minimize the risk for TB transmission, including MDR 
TB and XDR TB, to patients, workers, and others within the 
institutional setting.
Various infection-control strategies are available depend-
ing on whether a setting will provide primary care or triage 
and refer patients with suspected or confirmed TB disease. 
All infection-control strategies should be on the basis of a 
three-level hierarchy: administrative controls, environmental 
controls, and personal respiratory protection. Combinations of 
these infection-control strategies have been demonstrated to be 
effective at preventing TB transmission. However, these strat-
egies are not implemented consistently, and their individual 
effectiveness and feasibility are not well-characterized.
Problem 27
Although administrative controls, environmental controls, 
and respiratory protection have been effective when used in 
combination, ethical issues have prevented assessment of their 
individual effectiveness in settings in which TB transmission 
occurs. Resulting knowledge gaps hamper efforts to prioritize 
interventions for optimal cost-benefit in resource-limited 
settings.
objective 27.1
Ensure dissemination and implementation of currently 
recommended infection-control strategies across a range of high-
risk institutional settings (e.g., health-care facilities, substance 
abuse clinics, residential treatment centers, homeless shelters, 
and correctional and detention facilities) through education and 
regulatory programs (domestic and international).
Action Steps
27.1.1. Conduct a public health information campaign 
to encourage dissemination of recommended TB infection-
control procedures to U.S. health-care settings (inpatient and 
outpatient) that provide TB care, institute measures to track 
implementation of these measures, and identify barriers to 
implementation.
27.1.2. In collaboration with high-burden country health-
care providers, identify and prioritize TB infection-control 
procedures appropriate for health-care settings (inpatient 
and outpatient) in resource-limited areas where TB care is 
provided.
27.1.3. Provide regularly scheduled updates to CDC’s 
infection-control guidelines for health-care settings and related 
documents (e.g., guidelines for correctional and detention 
facilities) (26,30) and provide clarification as needed.
27.1.4. Develop guidance statements on TB prevention in 
HIV-infected and other immunocompromised health-care 
workers.
27.1.5. Disseminate and implement recommendations 
for use of airborne infection isolation rooms for known or 
suspected TB patients and use of local exhaust ventilation for 
aerosol generating procedures on these patients.
27.1.6. Disseminate and implement guidelines for selection, 
use, and appropriate re-use of certified respiratory protective 
devices used to protect against infection with M. tuberculosis 
in domestic and international settings including those with 
resource constraints.
27.1.7. Disseminate, implement, and regularly update rec-
ommendations for design, application, installation, monitor-
ing, and maintenance of both upper air and in-duct ultraviolet 
germicidal irradiation (UVGI) fixtures.
27.1.8. Develop guidelines for effective administrative and 
environmental measures to prevent M. tuberculosis transmis-
sion in homeless shelters, community residences for special 
needs populations, correctional and detention facilities, and 
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substance-abuse treatment centers. Guidelines are needed for 
correctional and detention facilities that can be applied inter-
nationally; guidelines for domestic correctional and detention 
facilities were published in 2006 (32) but might be relevant 
only to other industrialized countries with similar correctional 
systems and similar TB case rates.
27.1.9. Provide technical assistance to substance-abuse 
centers, shelters for the homeless, community residences for 
special needs populations, correctional and detention facilities, 
and health-care settings to determine the adequacy of local 
administrative controls, environmental controls and respiratory 
protection to minimize transmission of M. tuberculosis.
27.1.10. Regularly interact and communicate with regulatory 
agencies (e.g., Occupational Safety and Health Administration 
[OSHA]) and standard-setting organizations (e.g., the Joint 
Commission [formerly the Joint Commission on Accreditation 
of Healthcare Organizations (JCAHO)]; the American Society 
of Heating, Refrigerating and Air-Conditioning Engineers 
[ASHRAE]; and the American Institute of Architects [AIA]) 
to ensure that infection-control standards and guidelines for 
preventing M. tuberculosis transmission are consistent.
Lead federal agencies: HHS (CDC, FDA, HRSA, and 
Substance Abuse and Mental Health Services Administration 
[SAMHSA]), USAID, DHS (ICE), DOJ (BOP and USMS), 
VA, and HUD.
Suggested collaborators: OSHA, Healthcare Infection 
Control Practices Advisory Committee (HICPAC), Association 
for Professionals in Infection Control and Epidemiology 
(APIC), JCAHO, ASHRAE, AIA, state and local health depart-
ments, WHO, IUATLD, and national health ministries.
Problem 28
Tuberculin skin-testing programs are not implemented 
consistently in the United States.
objective 28.1
Ensure adequate TB testing programs for workers are avail-
able on site in settings with a substantial risk for transmission 
of M. tuberculosis (domestic).
Action Steps
28.1.1. Implement guidelines and requirements for 
improved institutional TB risk assessments in collaboration 
with OSHA and JCAHO to enhanced TB screening and 
monitoring procedures.
28.1.2. Recommend considering positive tuberculin skin 
test (TST) or blood assay (BAMT) for identification of M. 
tuberculosis infection among health-care workers as an out-
come measure of the effectiveness of TB infection-control 
programs in health-care facilities that are in the medium risk 
category or have been classified as having potential ongoing 
transmission.
28.1.3. Provide health departments with support in recruit-
ment of and assistance to health-care centers, correctional 
facilities, homeless shelters, and substance-abuse treatment 
centers to implement and assess the effectiveness of programs 
for systematic TB screening of workers employed in medium- 
or high-risk settings.
Lead federal agencies: HHS (CDC).
Suggested collaborators: OSHA, JCAHO, and state and 
local health departments.
Clinical and Programmatic 
Interventions
The fundamental principles and practices of TB control 
have been described previously (3,33). These principles and 
practices underlie the clinical and programmatic components 
of diagnosis, reporting, treatment and prevention of drug-
resistant TB addressed in this Task Force Plan 
Persons at risk for TB disease often fail to access health-care 
systems for a variety of complex reasons. A lack of under-
standing of TB and its symptoms, lack of financial resources 
(e.g., health insurance or transportation to the clinic), lack of 
awareness of free clinical services for TB, concerns of deporta-
tion and stigmatization, and existence of competing priorities 
(e.g., shelter and food) all contribute to delays in TB diagnosis 
and result in prolonged TB transmission in the community. 
Clinical and programmatic services must be integrated with 
and closely coordinated with TB laboratory services through 
a systems approach to ensure successful diagnosis and case 
management. Once patients access care, lack of familiarity 
with TB by health-care providers might result in misdiagnosis 
and inappropriate treatment, which in turn can lead to devel-
opment of drug resistance and continued transmission of M. 
tuberculosis. Once a TB diagnosis has been established, provid-
ing clinical TB services (preventive, diagnostic, and treatment/
case-management) that are culturally acceptable, affordable and 
logistically accessible to patients is a prerequisite for successful 
TB management and treatment completion.
Throughout the process of clinical care of TB patients, 
infection-control practices must be implemented properly, 
and health-care providers (physicians, nurses, pharmacists, 
dentists, laboratorians, other allied health professionals, tra-
ditional healers) must be educated thoroughly and trained in 
all principles and practices of TB care. To sustain consistent 
high quality and prompt care of TB patients, monitoring and 
evaluation programs must be established to identify rapidly 
systems failures and implement corrective measures. The ele-
ments of the health system that are necessary to prevent the 
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Figure. Prevention of development and transmission of drug-resistant tuberculosis (TB)
 * Latent TB infection.
 † Human immunodeficiency syndrome–positive.
 § Health-care worker.
 ¶ Household.
 ** Acid fast bacillus.
 †† Antiretroviral therapy.
development and transmission of MDR TB and XDR TB 
have been identified (Figure). Failures at any of the necessary 
steps related to proper TB diagnosis, treatment and infection-
control measures can lead to the development or transmission 
of drug-resistant TB.
The United States needs to assist international TB control 
programs in the development of clinical and programmatic 
practices that follow international standards for TB diagnosis 
and care, laboratory services, and infection control. Support 
should be provided to ensure that TB patients receive services 
free of charge and have access to DOT through the completion 
of treatment. The implementation of international informa-
tion sharing mechanisms is critical for the prevention of drug 
resistance and the successful control of TB worldwide.
Problem 29
TB patients might not have access to care.
objective 29.1
Increase the number of TB suspects at risk for MDR TB and 
XDR TB who seek and access care (domestic).
Action Steps
29.1.1. Develop and disseminate education materials for 
groups at risk for TB and MDR TB and XDR TB to increase 
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understanding of TB symptoms (especially early symptoms), 
transmission, and treatment. Materials and interventions 
should be presented in a way that engenders trust in health-
care institutions and helps to destigmatize patients with TB 
disease.
29.1.2. Provide support and consultation to groups using 
culturally appropriate education formats and language (includ-
ing those geared to persons who are illiterate) to promote an 
understanding of the availability of and how to access TB 
treatment free of charge.
29.1.3. Distribute the Patients’ Charter for Tuberculosis Care 
(34), which describes patients’ rights and responsibilities in 
languages appropriate to the patient population.
29.1.4. Develop interventions that are culturally and linguis-
tically appropriate to remove barriers or obstacles and assist 
patients in accessing care in a continuous manner, emphasizing 
clinic hours, transportation, and overcoming other barriers to 
improve treatment adherence and prevent the development 
and transmission of drug-resistant strains.
29.1.5. Evaluate interventions to ensure that they are cultur-
ally appropriate and effective in increasing patient access to TB 
diagnosis and treatment.
Lead federal agencies: HHS (CDC and HRSA).
Suggested collaborators: state and local health departments 
and RTMCCs.
Problem 30
Initial point-of-contact (POC) providers (e.g., emergency, 
urgent, primary, and correctional care providers; university 
health service and occupational medicine clinicians; health 
department clinicians; civil surgeons††; and traditional healers) 
might not suspect TB or have current or complete informa-
tion about the diagnosis and/or treatment of TB (see Problem 
44).
objective 30.1
Provide POC providers who serve at-risk persons with educa-
tion and guidance to increase their knowledge of TB and increase 
their access to resources to avoid misdiagnosis, prolonged trans-
mission, and inappropriate treatment (domestic).
Action Steps
30.1.1. Promote general knowledge of TB among providers 
through specific TB curricula and self-study modules. Educate 
providers about the critical importance of patient-centered 
case management and how to deliver high-quality services 
needed to ensure patient adherence and treatment completion. 
Explain the risks associated with undiagnosed, misdiagnosed, 
and inappropriately or inadequately treated TB.
30.1.2. Promote practices such as use of treatment regimens 
on the basis of national guidelines, DOT, prompt adjustment 
of treatment in response to DST results, patient incentives 
and enablers to maintain adherence, monitoring of response 
to treatment, and comprehensive case management in close 
collaboration with the local TB control program and treatment 
experts to prevent development and amplification of drug 
resistance among all TB patients.
30.1.3. Conduct a national media campaign to raise aware-
ness of TB for the general public and health-care providers.
30.1.4. Engage medical professional associations to raise 
awareness of TB and TB guidelines.
30.1.5. Review TB screening procedures and protocols for 
institutional facilities and primary care providers to assure 
competency and develop links between POC providers, local 
and state health departments and RTMCCs for diagnosis and 
referral of suspects.
30.1.6. Develop and distribute current regional, national 
and international MDR/XDR surveillance charts to health-
care providers and public health programs to inform them of 
high-prevalence areas for MDR TB and XDR TB.
30.1.7. Address health-care provider fears about MDR TB 
and XDR TB through discussions with medical societies, for-
mal and informal presentations with health-care professionals 
at meetings, and through targeted mailings.
30.1.8. Evaluate changes in POC awareness of diagnostic 
and treatment issues related to susceptible and resistant TB 
(see Problem 44 for additional action steps).
Lead federal agencies: HHS (CDC and HRSA), and BOP.
Suggested collaborators: NTCA, state and local health 
departments, health-care professional associations, state and 
local correctional facilities, homeless shelters, and RTMCCs.
Problem 31
Clinicians’ ability to diagnose XDR TB often is 
inadequate.
objective 31.1
Improve clinicians’ ability to diagnosis XDR TB, especially 
in immunocompromised persons (domestic).
Action Steps
31.1.1. Address provider concerns or fears about transmis-
sion and treatment of XDR TB.
31.1.2. Evaluate provider ability to diagnose TB and drug-
resistant TB.
 †† Designated physicians who examine aliens in the United States who apply for 
adjustment of their immigration status to that of permanent residents.
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31.1.3. Educate health-care providers on the need for expe-
dited drug-susceptibility testing immediately after an initial 
TB diagnosis, especially in high-risk congregate settings and 
in immunocompromised persons, to reduce morbidity and 
mortality in persons with drug-resistant TB.
31.1.4. Update TB care guidelines to recommend routine 
HIV testing during initial patient evaluation for TB on the 
basis of opt-out testing§§ recommended by CDC.
31.1.5. Develop and distribute regularly updated regional, 
national and international MDR TB and XDR TB surveillance 
charts to health-care providers and public health programs to 
increase awareness of the extent of drug-resistant disease in 
patients who do not respond to first-line therapy.
31.1.6. Develop a system of consultation and patient 
referral between primary care physicians (including HRSA 
Community Health Centers, primary care HIV clinics, and 
homeless programs), physicians in correctional or detention 
settings, departments of health, and RTMCCs to improve 
diagnosis and management of TB patients, especially those 
with MDR TB and XDR TB.
31.1.7. Discuss with FDA requirements for review and 
approval of rapid tests to detect rifampin resistance (RIF) as 
a primary/surrogate indicator for MDR TB and XDR TB 
and define special situation where use of rapid RIF assays and 
other molecular tests to diagnose drug resistance would be 
appropriate.
Lead federal agencies: HHS (CDC, FDA, and HRSA).
Suggested collaborators: NTCA, RTMCCs, state and local 
health departments, and health-care provider professional 
societies.
Problem 32
Existing diagnostic protocols used for screening foreign-born 
persons entering, or already residing in the United States, are 
not sufficient to detect XDR reliably.
objective 32.1
Improve currently used protocols for TB screening among 
foreign-born persons to facilitate rapid detection of XDR TB 
(Domestic)
Action Steps
32.1.1. Review and update instructions for civil surgeons and 
other health-care providers involved in screening of foreign-
born persons after arrival in the United States to facilitate early 
identification and prompt treatment of drug-resistant TB.
32.1.2. Develop certification processes for Civil Surgeons 
and others health-care providers who provide TB screening to 
assure consistency and proficiency in diagnostic procedures.
32.1.3. Evaluate procedures for monitoring and quality con-
trol of updated screening procedures for TB and MDR TB and 
XDR TB to assure adequate and consistent implementation.
Lead federal agencies: HHS (CDC, HRSA), and DHS 
(ICE).
Suggested collaborators: DOS, state and local and health 
departments, and civil surgeons.
Problem 33
Effective and safe treatment regimens for XDR TB have not 
been established.
objective 33.1
Identify appropriate treatment regimens for TB resistant to 
various types and combinations of chemotherapeutic agents 
(domestic and international).
Action Steps
33.1.1. Perform literature analysis to document and summa-
rize experience with treatment regimes and associated clinical 
outcomes for patients with XDR TB.
33.1.2. Develop guidance for empiric treatment of persons 
with suspected XDR TB before availability of DST results with 
regionally appropriate standardized regimens.
33.1.3. Develop recommendations for treatment of XDR 
TB on the basis of available resistance patterns.
Lead federal agencies: HHS (CDC) and USAID.
Suggested collaborators: WHO, IUATLD, state and local 
health departments, and national ministries of health.
Problem 34
The quality of currently available services and treatment 
for XDR TB patients has not been monitored or evaluated 
sufficiently.
objective 34.1
Improve the quality and effectiveness of free clinical services, 
medications and treatment regimens as part of patient-centered 
management for patients with XDR TB (domestic).
Action Steps
34.1.1. Develop and implement fully supported, improved 
patient-centered clinical services for outpatient management 
of persons with XDR TB that ensure full cooperation and 
maximum chance of success.
34.1.2. Develop and implement procedures and due process 
and recommendations for legal recourse for management of 
 §§ Defined as performing HIV testing after notifying the patient that the test will 
be performed and consent is inferred unless the patient specifically declines.
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XDR TB patients refusing treatment or care to minimize risk 
to communities (see Problems 39, 41, and 42).
34.1.3. Identify centers of excellence for in-patient treatment 
of MDR TB and XDR TB that are available for consultation on 
and referral of XDR TB patients to optimize care and increase 
likelihood of cure.
34.1.4. Evaluate whether XDR TB centers of excellence 
might be developed as national referral centers for all patients 
with XDR TB to provide the best possible care, increase treat-
ment success and reduce transmission to others.
34.1.5. Develop procedures for transfer of patients to referral 
centers and identify funding to support the cost of treating 
and managing XDR TB patients.
34.1.6. Establish programs to facilitate collaboration between 
XDR TB centers of excellence and the RTMCCs for ongoing 
medical education, consultation, and technical assistance to 
community providers on all aspects of care of MDR TB and 
XDR TB patients.
34.1.7. Develop processes and procedures for referral and 
care of patients who are in legal custody during inpatient or 
outpatient treatment to ensure appropriate discharge and con-
tinuity of care when released from custody or transferred to a 
different detention facility or law enforcement agency.
34.1.8. Develop processes to request a stay of removal for 
patients slated for deportation to a country where treatment is 
not likely to be available and establish procedures and resources 
to complete TB treatment in the United States, including 
provision of secure environments, if appropriate.
Lead federal agencies: HHS (CDC and HRSA), DHS (ICE), 
and DOJ (BOP and USMS).
Suggested collaborators: state and local health departments, 
RTMCCs, existing specialized TB treatment centers (e.g., 
National Jewish Research and Medical Center, Shattuck 
Hospital, AG Holley Hospital, and Texas Center for Infectious 
Diseases), ATS, and IDSA.
Problem 35
MDR TB patients most at risk for XDR TB might not 
adhere to treatment.
objective 35.1
Address known barriers to treatment adherence for MDR 
TB patients at risk for XDR TB through sustainable solutions 
(domestic).
Action Steps
35.1.1. Implement routine program evaluations and techni-
cal assistance for domestic TB programs to identify weaknesses 
that might lead to inappropriate therapy, treatment failures 
and the development of drug resistance.
35.1.2. When appropriate, assure the use of DOT through-
out treatment for patients with MDR TB and XDR TB.
35.1.3. Recommend the use of fixed-dose drug combinations 
(pills that contain a fixed dose of multiple medications) in the 
United States to facilitate treatment adherence.
35.1.4. Provide appropriate incentives and enablers to facili-
tate treatment adherence.
35.1.5. Ensure continuity of care for foreign-born and other 
high-risk patients who might face deportation or who are 
traveling frequently between jurisdictions.
Lead federal agencies: HHS (CDC and HRSA), DHS (ICE), 
and DOJ (BOP and USMS).
Suggested collaborators: state and local health departments, 
TBNET, and CureTB.
Problem 36
Experienced health-care workers and health-care providers 
with substantial expertise in TB care and management have 
left the workforce for retirement and have not been replaced 
in sufficient numbers to assure continuity of quality care.
objective 36.1
Increase the number of trained TB health-care workers 
(domestic and international).
Action Steps
36.1.1. Develop, disseminate and endorse use of model 
TB curricula in nursing, medical, and allied health education 
institutions.
36.1.2. Post TB job openings at universities that are teach-
ing TB curricula.
36.1.3. Provide academic awards for exceptional performance 
in TB research, interventions, and communications.
36.1.4. Conduct pre-service and in-service training of health 
personnel.
Lead federal agencies: HHS (CDC, NIH, and HRSA) and 
USAID.
Suggested collaborators: NTCA, nursing, medical, and allied 
health professional associations and education institutions, 
Association of State and Territorial Health Officers (ASTHO), 
APHL, Association of Schools of Public Health, and academia 
(including historically black colleges and universities to address 
workforce diversity).
Problem 37
Safe, effective treatment regimens and appropriate follow-up 
procedures for managing contacts of XDR TB patients have 
not been established.
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objective 37.1
Prevent transmission to and development of XDR TB among 
contacts of XDR TB patients.
Action Steps
37.1.1. Evaluate the effectiveness and safety of proposed 
regimens and/or follow-up procedures for contacts of XDR 
TB patients.
37.1.2. Develop and disseminate to private and public 
health-care providers CDC recommendations for treatment 
and follow up of contacts of patients with XDR TB and enlist 
the endorsement of medical and nursing societies to ensure 
compliance with treatment recommendations.
37.1.3. Encourage community physicians and others with 
limited experience or expertise in managing MDR TB and 
XDR TB to consult with centers of excellence for possible 
referral of patients for treatment and management.
Lead federal agencies: HHS (CDC).
Collaborators: state and local health departments, RTMCCs, 
ATS, IDSA, and NTCA.
Problem 38
Resources and/or technical capacity to adequately address 
TB and XDR TB are not universally available outside the 
United States.
objective 38.1
Increase U.S. assistance to TB and XDR TB programs, espe-
cially to TB-endemic countries from which substantial numbers 
of persons immigrate to the United States (international).
Action Steps
38.1.1. Support WHO’s plan to respond to the global prob-
lem of XDR TB (26).
38.1.2. Contribute to international efforts to strengthen TB 
and TB/HIV control activities such as universal use of DOT 
to reduce default rates, improvement of laboratory/diagnostics 
capacity and quality, provision of antiretroviral treatment for 
persons co-infected with HIV, targeted TB screening in at-risk 
persons and support for the creation of regional training and 
treatment centers to optimize care and prevent the develop-
ment of drug resistance.
38.1.3. Contribute to the expansion of supranational labora-
tory capacity, quality assessment programs and training to ensure 
rapid and accurate diagnosis of TB and drug-resistant TB.
38.1.4. Assist in the recruitment and training of health-care 
workers in basic TB management and the early recognition of 
indicators suggestive of drug-resistant TB.
38.1.5. Review the technical instructions for panel physi-
cians¶¶ who conduct TB screening as part of immigration 
procedures with regard to XDR TB diagnosis and contact man-
agement and develop a process to certify panel physicians.
38.1.6. Support and recommend the use of fixed-dose drug 
combinations when appropriate and provide training and 
technical assistance to improve TB drug management.
38.1.7. Provide technical assistance through full-time con-
sultants to ministries of health in countries that are sources 
of large numbers of U.S. immigrants and countries with a 
high burden of drug-resistant TB to support completion of 
ongoing drug-resistance surveys and the establishment of 
drug-resistance surveillance systems.
38.1.8. Provide resources and support to establish U.S.-
transnational TB case management programs such as interna-
tional referral programs and information-sharing system.
Lead federal agencies: USAID, HHS (CDC, HRSA), and 
DHS (ICE).
Suggested collaborators: DOS, WHO, IUATLD, Green 
Light Committee (GLC), Medicins Sans Frontieres (MSF), 
and KNCV.
Ethical and Legal Issues
TB is a reportable infectious disease, and public health 
protection and TB control activities are described in specific 
state laws. Many existing laws were established before the 
contemporary public health recommendations for the preven-
tion and control of TB became available (6,35). As a result, 
the Advisory Committee for the Elimination of Tuberculosis 
(ACET) and CDC conducted a survey of state TB control 
laws and regulations and developed recommendations that 
addressed legal issues of TB control in the United States. Since 
these recommendations were published (29), no systematic fol-
low up has been conducted to determine the extent to which 
these recommendations were implemented.
Problem 39
Laws and regulations permitting authorities to compel 
treatment and isolation of patients with tuberculosis vary by 
state.
objective 39.1
Encourage states to review existing laws to ensure they are 
adequate to deal with XDR TB patients (domestic).
 ¶¶ Designated physicians who examine all refugees coming to the United States 
and all applicants outside the United States applying for immigrant visas 
before travel to the United States.
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Action Steps
39.1.1. Encourage states to develop a contemporary model 
state law through a public process that defines criteria, 
situations and conditions under which compulsory treat-
ment and isolation of patients with infectious TB should be 
considered.
39.1.2. Provide support and recommendations for review, 
clarification and update of state and local tuberculosis control 
laws.
Lead federal agencies: HHS (CDC).
Suggested collaborators: state and local health departments, 
law schools and state legislatures.
Problem 40
Public health authorities in the United States have only 
limited understanding of public health law pertaining to infec-
tious diseases of public health significance in Mexico and other 
neighboring countries.
objective 40.1
Increase knowledge among U.S. state public health officials 
regarding public health laws pertaining to infectious diseases 
in countries neighboring the United States (domestic and 
international).
Action Steps
40.1.1. Convene a legal forum to address legal require-
ments and interventions to avert public health threats that 
might arise from patients crossing international jurisdictional 
boundaries.
40.1.2. Translate public health laws from countries neigh-
boring the United States into English for distribution to U.S. 
public health officials.
40.1.3. Establish a repository of binational and transnational 
public health legal information in English and Spanish.
Lead federal agencies: HHS (CDC and HRSA), DHS (ICE 
and CBP), and DOJ.
Suggested collaborators: state and local health departments, 
law schools, and national justice and health ministries.
Problem 41
The effectiveness of mandated isolation or quarantine to 
compel treatment for TB patients as compared to less restrictive 
measures, and the ethical issues associated with these measures, 
have not been evaluated closely.
objective 41.1
Develop guidelines and a research agenda to determine the 
effectiveness of and ethical issues associated with compelling 
treatment and isolation for TB patients who are considered a 
threat to public health (domestic).
Action Steps
41.1.1. Conduct research to determine the impact and 
effectiveness of mandatory isolation to compel treatment for 
tuberculosis as compared with less restrictive measures.
41.1.2. Conduct research on ethical issues of mandated iso-
lation (or quarantine) and less restrictive measures to compel 
treatment for tuberculosis.
41.1.3. Convene a workshop for bioethicists and TB con-
trol, care, and research professionals to identify and catalog 
key ethical issues likely to be confronted as part of the XDR 
TB response.
Lead federal agencies: HHS (CDC and NIH), DHS, and 
DOJ.
Suggested collaborators: state and local health departments, 
law schools, and academia (biomedical ethicists).
Problem 42
Patients with XDR TB could require prolonged isolation 
measures regardless of the patient’s adherence to treatment, 
which might present an ethical dilemma in balancing the 
interests of public health with those of the patient.
objective 42.1
Develop guidance on ethical issues pertaining to prolonged 
isolation of patients with XDR TB who are fully adherent to 
treatment (domestic).
Action Steps
42.1.1. Conduct research on ethical considerations of pro-
longed, mandated isolation including contexts of fully adherent 
patients and those who are in the terminal stages of disease.
Lead federal agencies: HHS (CDC and NIH), DHS, and 
DOJ.
Suggested collaborators: state and local health departments, 
law schools, and academia (biomedical ethicists).
Problem 43
Obstacles to compassionate use of experimental chemo-
therapeutic agents for patients with XDR TB limit critically 
important therapeutic options.
objective 43.1
Address the obstacles to and identify solutions for compas-
sionate use access of new experimental therapeutic agents for 
treatment of XDR TB patients (domestic).
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Action Steps
43.1.1. Initiate discussion with public and private sector 
organizations involved in TB drug development to define 
components of viable compassionate use programs to access 
experimental chemotherapeutics for XDR TB patients.
43.1.2. Contribute to the development of compassionate 
access programs in collaboration with pharmaceutical partners 
and FDA.
Lead federal agencies: HHS (CDC, FDA, and NIH).
Suggested collaborators: state and local health departments, 
RTMCCs, academia, and the pharmaceutical industry.
Communication and Education
Comprehensive and tailored information on TB and drug-
resistant TB including XDR is needed for many different 
audiences. In the United States, private health-care providers 
(i.e., those not in public health departments) receive little 
education or training on detection and appropriate treatment 
of TB (11,30,31,36–38). As a consequence, infectious TB often 
goes unrecognized, even if a patient presents to a physician with 
apparent signs and symptoms of active disease. This has led 
to incorrect treatment, prolonged transmission of TB in the 
community, and creation of drug-resistant organisms.
Education and communication must be appropriately 
targeted to health-care providers and patients to improve 
awareness and guide access to competent clinical services. 
Community leaders and health policy makers, including public 
health officials, must be well informed about the need to com-
municate and address issues that can fuel the development and 
spread of drug-resistant TB in their communities. Education 
efforts should clearly outline the critical elements that must 
be applied to prevent and control TB in various settings and 
risk populations (34).
Clear, concise messages, easy to understand yet comprehen-
sive education materials and medical alerts should be developed 
and disseminated to the general public, TB patients, physicians 
and other health-care workers, health advocacy organizations, 
and decision makers, including legislators. These communi-
cations should be coordinated across Federal agencies and 
updated as necessary. Increasing awareness of the signs and 
symptoms of TB and the appropriate treatment and control 
strategies, must become a priority in the United States to 
ensure TB is recognized and treated as a public health threat 
with the potential to result in virtually untreatable forms of 
disease, such as XDR TB.
In TB-endemic countries where cases of drug-resistant TB 
are increasing, health authorities must also remain informed 
about the risk for and incidence of XDR TB. There, provider 
education initiatives must also focus on the need for appropri-
ate case management, including knowledge regarding locally 
and regionally available specialty resources and medications and 
the consequences of inappropriate or inadequate treatment of 
drug-resistant TB.
Problem 44
Health-care providers and the general public are not well-
informed about the symptoms, appropriate, diagnosis, treat-
ment, and prevention of drug-susceptible and drug-resistant 
TB including XDR TB.
objective 44.1
Develop education mechanisms and materials, targeted to 
public and private health-care providers and other workers 
who might come into contact with populations with a high 
prevalence of TB infection and disease in settings such as 
health-care facilities, homeless shelters and correctional facili-
ties, about drug-susceptible and drug-resistant TB including 
XDR, heighten awareness and encourage appropriate preven-
tion, diagnosis, treatment, and referral (domestic).
Action Steps
44.1.1. Review and update existing education materials and 
communication products on TB to include relevant informa-
tion about drug-resistant forms of disease.
44.1.2. Identify communication gaps and special needs 
for education and communication products regarding drug-
susceptible and drug-resistant TB and develop new materials 
as needed.
44.1.3. Communicate to health-care providers appropriate 
measures to prevent MDR TB and XDR TB, including the 
importance of detecting and treating LTBI and TB disease 
and the importance of prompt reporting of TB cases to proper 
health authorities.
44.1.4. Communicate to health-care providers the impor-
tance of consulting and engaging TB experts in the medical 
management of MDR TB patients to avoid the development of 
XDR TB and to ensure that appropriate specialized resources 
for treatment of drug-resistant TB are optimally used.
44.1.5. Familiarize health-care providers serving high-risk 
patients with TB training and medical consultation resources 
that are available through the RTMCCs.
44.1.6. Contribute to the dissemination and promotion of 
infection-control guidelines and supporting education materi-
als in the United States (28) and globally (39).
44.1.7. Develop strategies and materials on TB and MDR 
TB and XDR TB diagnosis, treatment, and reporting for dis-
semination at national medical and laboratory meetings.
44.1.8. Develop education materials for digital mass media, 
such as the Internet, personal digital assistants, and podcasts 
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to reach and inform health-care providers about control of all 
forms of TB.
44.1.9. Develop and distribute targeted education material 
to health-care providers and nontraditional partners who are 
not usually engaged in TB control activities such as primary 
care and nurse practitioners, physician assistants, emergency 
care and urgent care specialists, health-care providers in cor-
rectional facilities, civil surgeons, pharmacists, foreign-trained 
clinicians, non-U.S. health-care providers, university health 
service, occupational medicine specialists, rheumatologists, 
oncologists, radiologists, laboratories, traditional healers, 
NGOs, and CBOs.
44.1.10. Present specialty-specific information about care 
and control of all forms of TB at professional conferences.
44.1.11. Develop targeted TB training and education for 
other workers who might be exposed to TB in settings such 
as health-care facilities, homeless shelters and correctional 
facilities.
Lead federal agencies: HHS (CDC, NIH, and HRSA).
Suggested collaborators: RTMCCs, NTCA, ATS, American 
College of Chest Physicians (ACCP), IDSA, American 
Medical Association (AMA), American Association of Family 
Practitioners (AAFP), and APHL.
objective 44.2
Develop education mechanisms and materials to inform 
decision makers in the public and private sectors about priori-
ties and strategies for the prevention and control of TB and 
MDR TB and XDR TB (domestic).
Action Steps
44.2.1. Develop strategic plans for advocacy and com-
munications in collaboration with National TB Controllers 
Association, Results International, STOP TB USA, the 
American Thoracic Society, and other relevant organizations.
44.2.2. Provide assistance to federal and state TB programs 
to develop and use coordinated communication mechanisms 
to disseminate information about drug-susceptible and MDR/
XDR (e.g., California TB Controller Association newsletter, 
TB Notes, letters to colleagues, or TB Educate listserv).
44.2.3. Identify a designated contact person in health depart-
ments for states with a high incidence of TB disease to help 
facilitate media communications.
44.2.4. Develop mechanisms for networking and commu-
nications between state TB controllers, legislators and com-
munity leaders for populations affected by TB.
44.2.5. Establish conduits for regular and systematic com-
munication of relevant data on all forms of TB, TB control 
program successes and needs, and federal agency efforts related 
to MDR TB and XDR TB to policy makers.
44.2.6. Encourage TB programs to include policy makers 
and their staff on state and local advisory committees.
44.2.7. Identify resources to develop and promote public 
education/information campaigns.
Lead federal agencies: HHS (CDC, NIH, and HRSA).
Suggested collaborators: NTCA, ATS, IDSA, STOP 
TB USA, Results International, and state and local health 
departments.
objective 44.3
Integrate information on TB, MDR-TB, and XDR-TB 
prevention, diagnosis, and treatment into health promotion 
strategies of organizations with common interests in public 
health issues (domestic and international).
Action Steps
44.3.1. Develop strategic plans for advocacy and commu-
nications in collaboration with NTCA, Results International, 
STOP TB USA, ATS, and other relevant organizations.
44.3.2. Identify resources to develop and disseminate public 
education/information materials to inform community groups, 
managed care organizations, and provider groups about TB 
and MDR TB and XDR TB.
44.3.3. Identify resources to develop and disseminate public 
education/information materials on TB and MDR TB and 
XDR TB to inform staff and law enforcement officials in cor-
rectional and detention facilities, including ICE and CBP.
44.3.4. Establish communication channels through managed 
care organizations, medical and nursing societies and local 
chapters of professional organizations to disseminate informa-
tion about TB and MDR TB and XDR TB.
44.3.5. Develop mechanisms and collaborations to integrate 
information on XDR TB in education materials being devel-
oped for health-care providers in training through NTCC.
44.3.6. Contribute to the development and implementation 
of a strategic plan for advocacy and media communication 
with STOP TB Partnership working groups and TB patient 
representatives, high-burden country TB and HIV control 
managers, and other global advocates for TB.
Lead federal agencies: HHS (CDC, NIH, and HRSA), DHS 
(ICE and CBP), DOJ (BOP and USMS), and USAID.
Suggested collaborators: NTCA, Results International, 
STOP TB USA, NTCC, STOP TB Partnership, and state and 
local health departments.
objective 44.4
Establish and maintain mechanisms to facilitate regular 
communication among federal agencies, and with state and 
local TB control programs (domestic).
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Action Steps
44.4.1. Regularly update and disseminate information by the 
CDC, WHO, and other agencies on MDR TB and XDR TB 
to federal staff, TB control programs, HIV/AIDS programs, 
and other public health agencies and interested organizations 
to ensure that U.S. public health programs are well informed 
about the incidence and prevalence of drug-resistant TB in the 
United States and globally.
44.4.2. Identify federal TB Task Force members to serve as 
key spokespersons for issues related to MDR TB and XDR TB 
while ensuring that all Task Force members are well informed 
to contribute to the ongoing dissemination of information on 
all forms of TB.
44.4.3. Communicate on a regular basis efforts and relevant 
results and outcomes related to prevention and control of MDR 
TB and XDR TB by federal agencies.
Lead federal agencies: HHS (CDC and NIH).
Suggested collaborators: NTCA and state and local health 
departments.
Research
Biomedical research in TB creates a foundation of knowledge 
that informs the development of new health-care interventions 
as well as control and prevention strategies for drug-resistant 
TB. While U.S. federal agencies have substantially contributed 
to research in TB and the identification of drugs, vaccines and 
diagnostics, the emergence of more difficult to treat forms 
of drug-resistant TB will require renewed and more targeted 
efforts to help control and prevent the development and trans-
mission of drug-resistant forms of TB. One compilation of 
biomedical research priorities related to MDR TB and XDR 
TB has been published (7).
TB therapy was revolutionized in the 1940s by the develop-
ment of antibiotics by academic and for-profit organizations, 
and the demonstration of their efficacy and safety in random-
ized clinical trials largely conducted by the public sector. These 
therapies became the basis for the global DOTS strategy for 
TB control. Although initially highly effective in reducing 
the incidence and prevalence of TB in endemic countries, 
the continued success of the DOTS strategy is now seriously 
threatened by the emergence of highly drug-resistant strains 
of M. tuberculosis. Furthermore, interactions between TB and 
HIV medications and drugs used in the treatment of special-
ized problems such as diabetes, drug addiction and mental 
disorders (conditions that are encountered in populations at 
risk for TB) might substantially complicate the development 
of effective new TB drugs. To ensure the continued availability 
of effective therapeutics against all forms of TB, the develop-
ment of new, safe, and effective TB drugs must remain a high 
priority. Success in TB drug development will also heavily rely 
on the establishment and continued support of competent, 
experienced trial sites in TB and TB/HIV endemic countries 
for all phases of clinical testing.
Problem 45
Few new TB drugs are in preclinical and clinical 
development.
objective 45.1
Increase the number of candidates in all stages of the TB 
drug development pipeline to increase the likelihood that new 
agents will become available for clinical use within the next 
5-10 years (domestic and international).
Action Steps
45.1.1. Increase communication between private not-for-
profit and commercial organizations and relevant public sector 
agencies to identify opportunities for public/private collabora-
tions in TB drug development.
45.1.2. Reevaluate, refine, and optimize support for drug 
discovery and preclinical studies for pharmaceutical compa-
nies and academic/not-for profit organizations (in vitro and 
animal models).
45.1.3. Encourage pharmaceutical companies, academic 
researchers and nonprofit organizations to engage in TB drug 
development research and development efforts.
Lead federal agencies: HHS (CDC, FDA, and NIH) and 
USAID.
Suggested collaborators: Global Alliance for TB Drug 
Development, pharmaceutical industry, and academia.
Problem 46
The global capacity to conduct clinical trials for new drugs 
that treat TB and MDR TB and XDR TB is limited.
objective 46.1
Contribute to the development and support of global TB 
clinical trials sites and resources to facilitate clinical evaluation 
of new drugs for TB and MDR TB and XDR TB (domestic 
and international).
Action Steps
46.1.1. Participate in the assessment and evaluation of cur-
rent clinical trials sites for TB.
46.1.2. Establish collaborations to develop strategies for 
expansion of global TB trials, and associated laboratory capac-
ity within national and local TB control programs.
46.1.3. Establish collaborations to develop international 
standards and protocols to facilitate TB drug trials in MDR TB 
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and XDR TB patients and develop mechanisms to coordinate 
efforts with WHO and GLC.
46.1.4. Expand U.S. government funded clinical TB research 
efforts to include MDR TB and XDR TB when appropriate.
46.1.5. Establish collaborations to define laboratory stan-
dards for MDR TB and XDR TB clinical trials.
Lead federal agencies: HHS (CDC, FDA, and NIH) and 
USAID.
Suggested collaborators: Global Alliance for TB Drug 
Development, European and Developing Countries Clinical 
Trials Partnership (EDCTP), other national research agencies 
(e.g., British Medical Research Council (BRMC), SAMRC, 
and Tuberculosis Research Centre (TRC)-Chennai), academia, 
GLC, and WHO.
Problem 47
Well-validated surrogate markers do not exist to rapidly assess 
clinical efficacy of new chemotherapeutic agents and regimens 
against drug-susceptible and MDR TB and XDR TB.
objective 47.1
Contribute to the clinical definition and validation of sur-
rogate markers to shorten the duration of clinical trials to 
estimate the efficacy of new chemotherapeutic agents and 
regimens (domestic and international).
Action Steps
47.1.1. Encourage and support collaboration between 
researchers in diagnostics and immunology and TB clinical 
trials groups to facilitate access to well-characterized clinical 
specimens.
47.1.2. Initiate discussion with U.S. and other national 
regulatory agencies to define minimally acceptable data sets 
needed to accept surrogate markers for registration of new 
chemotherapeutic agents and regimens.
Lead federal agencies: HHS (CDC, FDA, and NIH).
Suggested collaborators: Global Alliance for TB Drug 
Development, pharmaceutical industry, other national research 
agencies (e.g., BMRC, SAMRC, and TRC-Chennai), and 
academia.
Problem 48
Effective treatments for latent MDR/XDR M. tuberculosis 
infection have not been established.
objective 48.1
Support clinical studies to identify effective treatment strate-
gies for LTBI caused by MDR and XDR M. tuberculosis.
Action Steps
48.1.1. Contribute to and support protocol development and 
clinical studies to evaluate new chemotherapeutic agents that 
were developed for active TB for treatment of drug-resistant 
LTBI.
Lead federal agencies: HHS (CDC, FDA, and NIH).
Suggested collaborators: Global Alliance for TB Drug 
Development, pharmaceutical industry, other national research 
agencies (e.g., BMRC, SAMRC, and TRC-Chennai), and 
academia.
Problem 49
The types of clinical data needed to support registration of 
new chemotherapeutic agents against TB have not been clearly 
defined making it difficult to design effective clinical develop-
ment plans and timelines.
objective 49.1
Establish a forum for discussion between U.S. and inter-
national regulatory agencies to define specific guidance for 
clinical development and approval of chemotherapeutic agents 
indicated for use in MDR TB and XDR TB (domestic and 
international).
Action Steps
49.1.1. Contribute to and support workshops and discus-
sion among organizations involved in TB drug development 
and regulatory agencies to better define guidelines for clinical 
development and approval of new TB agents.
49.1.2. Encourage and support discussions between regula-
tory agencies and the private sector to facilitate development 
of compassionate use protocols for new TB drugs.
Lead federal agencies: HHS (CDC, FDA, and NIH).
Suggested collaborators: Global Alliance for TB Drug 
Development, pharmaceutical industry, European Medicines 
Agency, and other international regulatory bodies.
Problem 50
Pharmacology of existing and new TB drugs, including 
interactions with antiretroviral medications commonly used 
among at-risk populations, has not been adequately assessed.
objective 50.1
Support extended pharmacologic studies (pharmacokinetics, 
pharmacodynamics, and pharmacogenetics), including those 
that better characterize drug exposure profiles of first-line, 
second-line, and new drugs and combination regimens among 
at-risk populations and TB and HIV/TB patients (domestic 
and international).
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Action Steps
50.1.1. Support pharmacologic studies of drugs and relevant 
combination therapies either independently or nested within 
ongoing clinical trials.
50.1.2. Encourage and support pediatric studies of individual 
drugs and relevant combination therapies.
Lead federal agencies: HHS (CDC, FDA, and NIH).
Suggested collaborators: Global Alliance for TB Drug 
Development, pharmaceutical industry, other national research 
agencies (e.g., BMRC, SAMRC, and TRC-Chennai), and 
academia.
Problem 51
Efficacy, safety and pharmacology of TB chemotherapeu-
tics are not well characterized in special populations such as 
children, injection drug users, persons with HIV/AIDS, and 
others.
objective 51.1
Encourage and support inclusion of special populations in 
clinical trials that investigate new and improved drug treat-
ment strategies for TB and MDR TB and XDR TB (domestic 
and international).
Action Steps
51.1.1. Initiate collaborations to develop clinical trial proto-
cols for evaluation of existing and new TB treatment regimens 
in special populations.
51.1.2. Encourage and support early and late stage clinical 
trials in special populations.
Lead federal agencies: HHS (CDC, FDA, and NIH).
Suggested collaborators: Global Alliance for TB Drug 
Development, pharmaceutical industry, other national research 
agencies (e.g., BMRC, SAMRC, and TRC-Chennai), and 
academia.
Fundamental Science
The foundation for development of new health-care interven-
tions in TB is a solid understanding of the interaction between 
M. tuberculosis and the host and how infection transitions to 
active disease. Knowledge acquired through basic research in 
these areas must be effectively leveraged in translational science 
(i.e., research that translates basic scientific discoveries into 
clinical applications). As a consequence of the sequencing of 
the genome of both the host and pathogen, the development 
of molecular tools to manipulate the pathogen, the establish-
ment of genomic and postgenomic technologies and tools, 
and the expansion of animal models available to study TB, 
many important questions in the pathogenicity of TB now 
can be addressed.
Although considerable progress in fundamental science (basic 
and translational) of TB has been made over the past decade, 
the availability of more tools, technologies and advanced 
methodologies has made it possible to create new hypotheses 
and revisit earlier observations to contribute to a more detailed 
understanding of the best points of intervention in TB treat-
ment, necessary characteristics of potential new TB vaccines, 
and what host/pathogen factors might be early indicators of 
infection, disease, drug resistance, and transmission. In addi-
tion, the effectiveness of current and new infection-control 
measures, such as negative pressure, high-efficiency particu-
late air filters, laminar flow, ventilation design on the basis 
of modeling approaches (e.g., computational fluid dynamics, 
ultraviolet germicidal irradiation, room air cleaners, and alter-
native air disinfection methodologies) should be evaluated in 
appropriate research settings.
Problem 52
The characteristics of M. tuberculosis (e.g., growth, physi-
ology, biochemistry, genetics, and molecular biology) are 
incompletely understood.
objective 52.1
Continue to support fundamental research on the biology of 
M. tuberculosis and the host responses to infection and disease 
(domestic and international).
Action Steps
52.1.1. Encourage and support studies to determine mecha-
nisms of acquisition of drug resistance by M. tuberculosis.
52.1.2. Encourage and support expanded research on the 
physiology, biochemistry, and structural biology of M. tuber-
culosis virulence factors and pathogenic mechanisms.
52.1.3. Encourage and support studies to determine the 
mechanisms of immunopathogenesis of TB.
52.1.4. Encourage and support increased efforts to deter-
mine the immunologic and biologic factors associated with 
or responsible for latency and reactivation of M. tuberculosis 
infection.
52.1.5. Support the development of advanced animal 
and computational model systems to support fundamental 
research in TB, taking advantage of new disciplines (e.g., 
genomics, postgenomics, and proteomics) and system biology 
techniques.
52.1.6. Continue to provide high quality research reagents 
to facilitate TB research.
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52.1.7. Expand efforts to identify and validate novel drug 
targets, vaccine strategies, diagnostic markers and research 
tools.
52.1.8. Encourage and support research on genomics of 
both M. tuberculosis and human/animal hosts, linking to 
genetic epidemiologic research to direct studies in transmis-
sion, pathogenicity, microbial host interactions, and disease 
progression.
52.1.9. Support studies to characterize manifestations of TB 
in pediatric and immunocompromised populations.
Lead federal agencies: HHS (CDC and NIH)
Suggested collaborators: Global Alliance for TB Drug 
Development, pharmaceutical industry, other national research 
agencies (e.g., BMRC, SAMRC, and TRC-Chennai), and 
academia.
Problem 53
The effectiveness of various individual strategies for prevent-
ing TB transmission has not been sufficiently evaluated in 
domestic and international health-care settings.
objective 53.1
Support basic and applied research to assess and/or improve 
the efficacy of various control methods for preventing trans-
mission of TB in health-care settings and in communities to 
contribute to evidence-based public health recommendations 
(domestic and international).
Action Steps
53.1.1. Review the efficacy and cost effectiveness of adminis-
trative and environmental controls and respiratory protection 
strategies used to prevent infection within relevant programs 
and recommend areas of improvement.
53.1.2. Support research to develop improved tools to elu-
cidate the environmental viability of airborne M. tuberculosis 
and design new and improved air disinfection methods.
53.1.3. Support research and efforts to develop effective, 
affordable methods for expedient isolation of contagious 
patients that do not require major facility modifications.
53.1.4. Encourage and support cost analyses for modify-
ing existing health-care settings, correctional and detention 
facilities, homeless shelters, community residences for special 
needs populations and other high-risk institutional settings to 
achieve compliance with current and future infection-control 
requirements.
53.1.5. Support research to characterize dose-infection rela-
tionships for airborne M. tuberculosis to inform risk assessment 
of infection in relation to reductions in exposure.
53.1.6. Develop protocols and support studies to evaluate 
the effectiveness of various administrative controls on the 
reduction of TB transmission.
53.1.7. Support research to objectively document and 
improve the ability of various environmental controls to reduce 
exposure to airborne M. tuberculosis.
53.1.8. Support research to develop objective measures 
to document and compare the ability of various respiratory 
protective devices to reduce exposure to M. tuberculosis and to 
establish evidence-based recommendations for use of nation-
ally certified respirators providing the appropriate level of 
protection.
Lead federal agencies: HHS (CDC and NIH), DHS (ICE), 
and DOJ (USMS and BOP).
Suggested collaborators: OSHA, WHO, health-care facili-
ties, academia, other national research agencies (e.g., BMRC, 
SAMRC, and TRC-Chennai)
Diagnostics
The prompt and correct diagnosis of drug-susceptible and 
drug-resistant TB is one of the cornerstones of effective TB 
control. Current diagnosis of pulmonary TB in endemic 
countries is limited to clinical evaluation combined with low 
sensitivity microbiologic tests. Available diagnostics do not 
offer the speed and sophistication needed to provide physicians 
in the field in high-burden countries with the information 
required to accurately diagnose drug- susceptible and drug-
resistant TB and to prescribe the most appropriate treatment 
regimens. Three distinct research and development areas need 
to be addressed:
microbiological diagnostics: rapid identification of drug-•	
resistance or drug-sensitive TB and levels/types of drug 
resistance;
clinical diagnostics: rapid identification of pulmonary •	
and nonpulmonary TB, accurate diagnosis of TB in 
HIV infected patients, reliable identification of latent 
M. tuberculosis infection and accurate exclusion of TB 
disease; and
response to treatment: follow-up of patients on empiric •	
therapy when drug resistance testing was not possible/
feasible (e.g., extrapulmonary TB).
Although certain diagnostics platforms might be technologi-
cally too advanced for field use in resource limited countries, 
these tests might nevertheless provide a substantial contribution 
to the advancement of new therapeutics for TB by allowing 
rapid assessment of response to therapy in clinical trials. Such 
measures are critical in settings with patients with extrapul-
monary TB and those where drug-susceptibility testing is not 
possible or delayed. Furthermore, rapid assessment of response 
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to therapy will help determine whether adequate regimens 
have been prescribed and might contribute to limiting the 
development of drug resistance.
Problem 54
Rapid, point-of-care identification of drug-sensitive and 
drug-resistant pulmonary and extrapulmonary TB among 
HIV-negative and HIV-positive adults and pediatric popula-
tions ands reliable early identification of latent M. tuberculosis 
infection are not yet possible (see Problem 15).
objective 54.1
Develop rapid, point-of-care diagnostics for the reliable 
identification of drug-sensitive and drug-resistant pulmonary 
and extrapulmonary TB disease and latent infection including 
in HIV infected patients and pediatric populations (domestic 
and international).
Action Steps
54.1.1. Provide increased support for basic research on the 
biology of M. tuberculosis, the host responses to infection and 
progression to active disease, and epidemiologic studies to iden-
tify immunologic and microbiologic markers of infection and 
progression to active disease for diagnostic development.
54.1.2. Encourage development of new TB diagnostics by 
the small business community under mechanisms available 
through U.S. government funding.
54.1.3. Facilitate the development of serological and 
immunological tests specific to M. tuberculosis infection, and 
the development of genotypic markers for the point-of-care 
identification of drug-resistant TB through access to well 
characterized patient specimens to determine sensitivity of dif-
ferent diagnostic tests for TB in patients with different levels of 
immune function and at different stages of clinical disease.
54.1.4. Encourage and support research, including research 
into advanced imaging technologies to improve currently avail-
able diagnostic tests for the identification of pulmonary and 
extrapulmonary TB and latent M. tuberculosis infection.
54.1.5. Support the evaluation of cost effectiveness and 
appropriate use of available and newly developed rapid 
methods for diagnosis of drug-sensitive and drug-resistant 
pulmonary and extrapulmonary TB and latent M. tuberculosis 
infection.
54.1.6. Support studies to determine the most effective 
diagnostic combination/algorithms for latent M. tuberculosis 
infection and promote their inclusion in ongoing TB control 
programs.
54.1.7. Support and provide training to health-care providers 
for new diagnostic tests in high-burden countries to expand 
the use of new tests.
54.1.8. Support studies to improve molecular epidemiologic 
tools and databases for contact investigation and to assess the 
impact of new diagnostics, drugs and vaccines.
54.1.9. Establish partnerships and contribute to collaborative 
networks to facilitate validation of new diagnostic tests as part 
of clinical trials in partnership with high-burden countries.
54.1.10. Initiate discussions with FDA to identify criteria 
that will have to be met for approval of new diagnostic tests for 
identification of drug-sensitive and drug-resistant pulmonary 
and extrapulmonary TB and latent M. tuberculosis infection.
54.1.12. Support clinical and operational studies to evaluate 
the contribution of new diagnostic strategies to the manage-
ment and treatment of HIV-associated TB and pediatric TB.
Lead federal agencies: HHS (CDC and NIH).
Suggested collaborators: FIND, Aeras Global TB Vaccine 
Foundation (AERAS), academia, and other national research 
agencies (e.g., BMRC, SAMRC, and TRC-Chennai).
Problem 55
Efforts to develop tests to rapidly characterize clinical 
response to new and improved drug regimens in clinical trials 
are limited.
objective 55.1
Develop serologic, immunologic, and microbiologic tests to 
assess response to treatment. Evaluate technologically advanced 
tests, which might or might not be feasible to implement in 
endemic countries, for measuring drug efficacy in clinical tri-
als of new therapeutics and regimens for TB (domestic and 
international).
Action Steps
55.1.1. Encourage and support basic research on the 
changes in host immunology as a result of drug treatment in 
TB patients.
55.1.2. Encourage and support evaluation of serologic tests 
in the context of drug treatment and response to therapy.
55.1.3. Establish partnerships and encourage collaborations 
to facilitate access to well characterized, longitudinally collected 
patient specimens from drug treatment trials to determine suit-
ability of diagnostic tests for measuring response to therapy.
55.1.4. Support studies to evaluate the cost effectiveness 
of including tests to assess response to therapy with empiric 
drug treatment.
55.1.5. Support studies to determine the most effective 
diagnostic combination/algorithms to measure response to 
therapy and promote inclusion in ongoing TB control pro-
grams, when appropriate.
55.1.6. Establish partnerships and contribute to collaborative 
networks to facilitate validation of tests to determine response 
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to therapy as part of clinical trials in partnership with high-
burden countries.
55.1.7. Establish partnerships and contribute to collabora-
tive networks to use response tests in clinical trials to assess 
the early efficacy of new drug regimens.
55.1.8. Initiate discussions with FDA to identify criteria 
that will have to be met for diagnostic tests to assess early 
response to therapy as part of the data provided for new drug 
registration.
Lead federal agencies: HHS (CDC, FDA, and NIH) and 
USAID.
Suggested collaborators: FIND, AERAS, academia, and 
other national research agencies (e.g., BMRC, SA-MRC, and 
TRC-Chennai).
Vaccines
Long-term control and ultimate elimination of TB likely 
will require an effective vaccine (40). Research to characterize 
needs for an effective vaccine, on the basis of immunological 
responses of persons infected with M. tuberculosis who do not 
become ill and animal models and comparisons with the cur-
rently used vaccine M. bovis Bacille Calmette-Guerin (BCG) 
have been supported for over a decade. BCG vaccine, usually 
administered once in infancy in countries with a moderate and 
high incidence of TB, is effective in preventing TB meningi-
tis and disseminated TB in children but has highly variable 
efficacy in preventing other forms of TB, especially in adults 
(41). Strategic plans for a TB vaccine have been developed, and 
support for biomedical research for the development of new, 
more effective vaccines and vaccinations strategies has resulted 
in progress to the point where several new vaccine candidates 
are now being evaluated in clinical trials. Nevertheless, a highly 
effective vaccine has remained elusive.
Increased capacity to allow entry of novel vaccine candidates 
into Phase I clinical studies and comparative studies of vac-
cine platforms in human trials will contribute substantially to 
understanding development needs for effective TB vaccines. 
However, assays and methodologies for preclinical validation 
and clinical characterization need to be standardized globally. 
Clinical trial protocols for the assessment of vaccination strate-
gies and the development of expertise to conduct clinical trials 
and immunological assays in TB endemic countries are needed 
to establish a robust infrastructure for TB vaccine research and 
development (R&D).
Problem 56
Current preclinical and clinical efforts in TB vaccine devel-
opment are not optimally coordinated.
objective 56.1
Facilitate and expedite the identification and clinical testing 
of new vaccine candidates and vaccination strategies (domestic 
and international).
Action Steps
56.1.1. Discuss the role of U.S. government partners in 
contributing to global TB vaccine R&D and identify areas of 
contribution.
56.1.2. Contribute to and assist in the global coordination 
of TB vaccine development and clinical testing.
56.1.3. Encourage and support clinical studies to assess the 
potential role of BCG vaccination in MDR TB and XDR 
TB outbreaks where no effective antibiotics are available to 
contribute to control strategies.
56.1.4. Encourage and support studies with subunit, peptide, 
vectored and DNA vaccines as adjuncts to therapy for MDR 
TB and XDR TB.
56.1.5. Establish collaborations with regulatory agencies 
worldwide to discuss harmonization of regulatory pathways 
for clinical development and approval of new drugs, vaccines 
and diagnostics for TB.
56.1.6. Encourage and support research on postexposure 
vaccination.
56.1.7. Continue to support resources and facilities for test-
ing of new TB vaccines in animal models.
56.1.8. Establish collaborations with U.S. government spon-
sored HIV immunology testing programs to discuss access to 
clinical specimens from TB vaccine trials.
56.1.9. Sponsor a workshop to update the U.S. Blueprint 
for TB Vaccine Development (40).
56.1.10. Encourage and support research on biological 
response modifiers, adjuvants, and therapeutic vaccines and 
vaccination strategies (immunotherapeutics of TB).
Lead federal agencies: HHS (CDC, FDA, and NIH).
Suggested collaborators: WHO, EU, AERAS, academia, 
and other national research agencies (e.g., BMRC, SAMRC, 
and TRC-Chennai).
Behavioral, Social, Clinical, and 
operational Science
Current TB therapy is complex and lengthy, and it can be 
associated with adverse reactions to medications. Patient adher-
ence often is difficult, leading to discontinuation of therapy; 
this results in relapse, continued transmission of disease, and, in 
some cases, the development of drug-resistant TB. Adherence 
is influenced by patient characteristics, differences in health-
care seeking behavior, assumptions about disease, the health-
care environment, the availability of adherence-enhancing 
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interventions, the quality of communication between patients 
and providers, the availability and use of education materi-
als to inform patients and families about TB, treatment and 
consequences of defaulting, the convenience of access to drugs 
for supervised treatment, and the quality of drugs available 
through TB control programs.
The complexity of factors underlying patient adherence and 
the importance of completing treatment for TB necessitates 
increased emphasis on patient-centered treatment options and 
a thorough understanding of behavioral and social interven-
tions that have to be in place to augment traditional TB control 
approaches. Operational research to improve care programs 
must include studies to characterize TB health services, case 
and data management practices, staff selection, training and 
retention incentives, physician training, management and 
organizational structure, relationships with the community, 
community perceptions of services, community resistance 
to public health services, and clinic policies and practices to 
provide the best possible environment for ensuring patient 
trust and treatment completion.
Problem 57
Patient adherence to TB chemotherapy is not optimal, and 
alternative methods for ensuring completion of therapy are 
not fully developed.
objective 57.1
Identify alternatives and adjuncts to currently used treatment 
protocols through behavioral research to improve adherence 
to therapy (domestic and international).
Action Steps
57.1.1. Encourage and support studies to develop and 
validate predictor instruments to identify patient, social and 
cultural factors associated with poor adherence to therapy and 
development of drug-resistant TB.
57.1.2. Continue to support research on cultural influences 
on health-care utilization and adherence among foreign-born 
persons and minority groups at risk for drug-resistant TB.
57.1.3. Encourage and support studies to determine the 
effectiveness of interventions to increase adherence, including 
incentives, supports (enablers), and provision of social and 
other health-care services offered through TB programs.
57.1.4. Support studies to evaluate the contribution of com-
munication styles of TB health-care providers to treatment 
outcomes.
57.1.5. Facilitate surveys of TB treatment practices of various 
health-care providers to determine discrepancies in practices 
that might contribute to poor adherence and development of 
drug-resistant TB.
57.1.6. Support studies to identify barriers to effective 
communication and implementation of effective practices by 
providers most likely to treat patients at risk for drug-resistant 
TB.
57.1.7. Support review of prior formative communications 
research and conduct new studies to identify innovative and 
effective education methods to reach populations with high 
disease prevalence.
57.1.8. Evaluate education strategies for targeting the health-
care providers of patients at risk for drug-resistant TB and 
identify shortcomings and barriers to communication.
Lead federal agencies: HHS (CDC, FDA, and NIH).
Suggested collaborators: state and local health departments, 
WHO, other national research agencies (e.g., BMRC, SAMRC, 
and TRC-Chennai), and academia.
Problem 58
Operational and clinical questions related to patient adher-
ence and optimal organization and structure of health services 
to ensure effective TB care remain unanswered.
objective 58.1
Identify operational, clinical and systems barriers to provid-
ing effective TB care and develop strategies for improvement 
(domestic and international).
Action Steps
58.1.1. Support the design and implementation of opera-
tional research studies to improve TB control programs and 
patient/provider communication and relationships.
Lead federal agencies: HHS (CDC, FDA, and NIH).
Suggested collaborators: WHO, other national research 
agencies (e.g., BMRC, SAMRC, and TRC-Chennai), and 
academia.
Partnerships
Because XDR TB presents a worldwide threat, a coordi-
nated international response will rely on effective partnerships 
between all organizations and governments that are involved 
in TB control programs, TB biomedical research and product 
development (Box). In addition, the establishment of new alli-
ances is needed to fill the critical gaps in the global response 
identified in this report. Currently, government agencies at all 
levels, international organizations, nongovernment organiza-
tions (NGOs), academic institutions, and the private sector 
are coordinating their efforts as members of the STOP TB 
Partnership. Furthermore, cross-disciplinary research and 
product development efforts are brought together through vari-
ous nonprofit organizations focused on developing affordable 
and effective drugs, vaccines and diagnostics. Representatives 
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Organization       Website
Aeras Global TB Vaccine Foundation   http://www.aeras.org
American College of Chest Physicians   http://www.chestnet.org
American Medical Association    http://www.ama-assn.org
American Thoracic Society     http://www.thoracic.org
Association for Professionals in  
  Infection Control and Epidemiology   http://www.apic.org
Association of Public Health Laboratories    http://www.aphl.org
Bill & Melinda Gates Foundation    http://www.gatesfoundation.org
Centers for Disease Control and Prevention    http://www.cdc.gov
CDC Foundation      http://www.cdcfoundation.org
Centers for Medicare and Medicaid Services    http://www.cms.hhs.gov
CureTB        http://www.cureTB.org
Executive Office of Immigration Review    http://www.usdoj.gov/eoir
Federal courts      http://www.uscourts.gov
Food and Drug Administration     http://www.fda.gov
Foundation for Innovative New Diagnostics   http://www.finddiagnostics.org
Global Alliance for TB Drug Development   http://www.tballiance.org
Global Drug facility      http://www.stoptb.org/gdf
Green Light Committee     http://www.who.int/tb/challenges/mdr/greenlightcommittee/en/ 
          index.html
Health Resources and Services Administration   http://www.hrsa.gov
Hospital Infection Control Practices Advisory Committee http://www.cdc.gov/ncidod/dhqp/hicpac.html
Immigration and Customs Enforcement    http://www.ice.gov
Infectious Diseases Society of America   http://www.idsociety.org
International Council of Nurses    http://www.icn.ch
International Union against Tuberculosis and Lung Diseases http://www.iuatld.org
KNCV Tuberculosis Foundation     http://www.kncvtbc.nl/Site/Professional.aspx?language=en-GB
Médecins sans Frontiéres     http://www.msf.org
National Institutes of Health     http://www.nih.gov
National Ministries of Health
National TB Programs
Occupational Health and Safety Administration   http://www.osha.gov
RESULTS International     http://www.results.org
StopTB       http://www.stoptb.org
Task Force for Child Survival & Development   http://www.taskforce.org
TBNet        http://www.migrantclinician.org/network/tbnet
Treatment Action Group     http://www.aidsinfonyc.org/tag
U.S. Agency for International Development    http://www.usaid.gov
U.S. Department of Health and Human Services   http://www.dhhs.gov
U.S. Customs and Border Protection    http://www.cbp.gov
U.S. Department of Homeland Security    http://www.dhs.gov
U.S. Department of Housing and Urban Development   http://www.hud.gov
U.S. Department of Veterans Affairs     http://www.va.gov
U.S. local and state TB control programs   http://www.cdc.gov/tb/pubs/tboffices.htm 
U.S. Marshals Service     http://www.usmarshals.gov
U.S. National TB Controllers Association    http://tbcontrollers.org/
U.S. National Tuberculosis Nurse Coalition    http://tbcontrollers.org/
U.S. Regional Training and Medical Consultations Centers  http://www.cdc.gov/tb/rtmcc.htm 
World Health Organization     http://www.who.int
Pharmaceutical companies
Academic institutions
*This list is not intended to be exhaustive but rather provides examples of entities that partner with the U.S. government in U.S. domestic and international 
TB control efforts.
BOX. Domestic and international partner organizations involved in tuberculosis (TB) research and control 
programs* 
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from United States government agencies are actively involved 
in these partnerships and contribute their knowledge and 
expertise to help address the national and global aspects of 
XDR TB.
The U.S. Federal Tuberculosis Task Force serves as a mecha-
nism to coordinate activities of various federal agencies that 
are involved in domestic and international TB prevention 
and elimination programs. Domestically, U.S. government 
agencies work closely with local and state TB control pro-
grams, academic institutions, professional associations, and 
pharmaceutical companies to assure the most effective use of 
available resources and to minimize duplication of effort. The 
expansion of existing partnerships to include management 
and prevention of XDR TB and other forms of drug-resistant 
TB will be important if TB is to be eliminated in the United 
States and worldwide.
Problem 59
Differing jurisdictions among public health agencies, scopes 
of work among nongovernment organizations, and varying 
country-specific public health policies, economic condi-
tions, and political commitments pose a substantial barrier to 
launching and focusing a coordinated response to TB (MDR 
TB and XDR TB and HIV/TB) in high-burden settings with 
the greatest needs.
objective 59.1
Optimize integration, coordination and synergy between 
U.S. government agencies, international organizations, and 
national TB/HIV programs to achieve reduction in disease 
rates through more focused prevention/intervention activities 
for MDR TB and XDR TB and HIV/TB and nonduplicative 
allocation of funding, staff and resources (international).
Action Steps
59.1.1. Develop programs or working groups to maximize 
cooperation between international organizations and to align 
resources for an efficient, resource sparing response in high-
burden countries.
59.1.2. Establish additional interagency agreements to for-
malize existing cooperative efforts, where feasible.
Lead federal agencies: USAID and HHS (CDC).
Suggested collaborators: WHO, STOP TB, IUATLD, 
KNCV, ministries of health, and national and local National 
TB Program (NTP) staff.
Problem 60
Currently available global funds are insufficient to mount a 
comprehensive response to XDR TB, particularly in settings 
with high rates of HIV/TB co-infection. Resources need to be 
focused on this emerging threat, on the basis of identification 
of specific needs.
objective 60.1
Educate global and domestic partners on the international 
problem of TB, what activities are ongoing and what gaps 
remain to provide an effective response to MDR TB, XDR 
TB, and HIV/TB (domestic and international).
Action Steps
60.1.1. Increase interactions within existing partnerships and 
with private sector organizations, companies, and foundations 
to increase awareness of the current gaps that affect a global 
response to TB. 
60.1.1. Develop media projects to call attention to the global 
problem of TB and HIV/TB and the rise in drug-resistant TB 
and outline the limitations of current ongoing efforts.
Lead federal agencies: USAID and HHS.
Suggested collaborators: WHO, STOP TB, IUATLD, 
Treatment Action Group (TAG), MSF, ATS, NTCA, Task 
Force for Childhood Survival and Development, IDSA, and 
the Bill & Melinda Gates Foundation.
Problem 61
Globally, human resources at all levels in national TB 
programs are insufficient and maintaining a well qualified 
workforce has been difficult due to the continuous exodus of 
qualified, experienced TB and/or HIV staff. Domestically, the 
number of medical professionals with experience in manag-
ing TB patients, much less MDR TB and XDR TB patients, 
has declined in parallel with TB cases. A critical need is to 
strengthen human resources at the local and state/provincial/
district level.
objective 61.1
Develop and use partnerships between organizations involved 
in workforce training and retention to increase the number of 
qualified personnel available to international TB and HIV/TB 
programs (domestic and international).
Action Steps
61.1.1. Contribute to the identification of appropriate 
partner organizations and the establishment of programs to 
describe barriers to effective hiring and retention of qualified 
personnel in high-burden countries.
61.1.2. Participate in the development of recommendations 
to improve hiring, training, and retention practices for person-
nel employed in TB and HIV/TB programs.
61.1.3. Provide technical assistance for assessing and updat-
ing current infection-control procedures and processes to create 
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a safe work place for health-care personnel with the ultimate 
goal to increase retention of employees.
Lead federal agencies: USAID and HHS (CDC and 
NIH).
Suggested collaborators: WHO, KNCV, Family Health 
International (FHI), Peace Corps, MSF, NTCA, RTMCCs, 
local and state TB control programs, Association of Schools 
of Public Health, and academia (including historically black 
colleges and universities to address workforce diversity).
Problem 62
Government and private biomedical research and product 
development activities in the United States might be dupli-
cative, limiting the effective use of available funds and the 
efficiency by which fundamental research findings can be 
translated into new health-care interventions.
objective 62.1
Establish a forum among U.S. organizations, government 
and private, providing funding, regulatory oversight and 
research direction for TB science and product development to 
coordinate efforts and ensure optimal use of available resources 
(domestic).
Action Steps
62.1.1. Convene representatives from U.S. organizations 
involved in TB research and product development to iden-
tify current barriers and needs for improved coordination of 
programs.
62.1.2. Establish and articulate the roles and responsibilities 
of each partner in furthering specific aspects of TB research 
and product development.
62.1.3. Identify key gap areas in translational research and 
develop recommendations for programs or new partnerships 
to address these gaps.
Lead federal agencies: HHS (CDC, FDA, and NIH) and 
USAID.
Suggested collaborators: NGOs, academia, local and state 
health departments, ATS, IDSA, and the pharmaceutical 
industry.
Problem 63
Biomedical and product development activities and regula-
tory activities are not coordinated optimally between U.S. and 
international governmental and private agencies. Insufficient 
coordination of research activities exists among the various 
international entities with commitments to support TB 
research, or with involvement in related activities such as 
medical regulation.
objective 63.1
Develop or support working groups or other mecha-
nism to facilitate coordination of research activities among 
U.S. and international governmental and private agencies 
(international).
Action Steps
63.1.1. Develop an effective and sustainable forum for 
coordinating TB research between U.S. and international 
agencies.
63.1.2. Establish and articulate the roles and responsibilities 
of each partner in furthering specific aspects of TB research 
and product development.
63.1.3. Identify key gap areas in translational research and 
develop recommendations for programs or new partnerships 
to address these gaps.
Lead federal agencies: USAID and HHS (CDC, FDA, and 
NIH).
Suggested collaborators: WHO, IUATLD, academia, ATS, 
IDSA, national ministries of health, Non-Governmental 
Organizations (NGOs), pharmaceutical industry, and 
KNCV.
Problem 64 
Outside of the public health community, only limited aware-
ness exists of the potential consequences of XDR TB for the 
United States and globally (see Problem 44).
objective 64.1
Establish and maintain partnerships with appropriate orga-
nizations within and outside the public health community to 
increase awareness of XDR TB among policy makers and the 
general public (domestic and international).
Action Steps
64.1.1. In collaboration with appropriate partners, 
develop coordinated and consistent education material to 
promote informed awareness of XDR TB in the U.S. and 
internationally. 
Lead federal agencies: HHS (CDC, NIH, and HRSA), 
USAID, and HUD.
Suggested collaborators: WHO, IUATLD, Results 
International, American Lung Association, Treatment Action 
Group, local and state health departments, academia, and 
national ministries of health.
Problem 65
Current public health partnerships are not sufficient to 
ensure continuity of care for TB patients and their contacts 
who either reside temporarily in the United States or frequently 
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cross its borders. More than half the TB cases in the United 
States occur among immigrants who become infected before 
their arrival in the United States. Lack of continuity of care 
contributes to treatment default, ongoing transmission, and 
prolonged illness. Partnerships are needed for effective trans-
national case management.
objective 65.1
Identify appropriate partners and programs to contribute to 
projects and strategies that ensure continuity of TB care for 
patients traveling or migrating into or out of the United States 
(domestic and international).
Action Steps
65.1.1. Identify domestic and international partners to 
participate in an assessment of barriers to continuity of care 
for migrants or traveling TB patients.
65.1.2. Develop and implement transnational partnerships 
that allow establishment of cross-border TB care and manage-
ment programs, such as the Bi-National TB Card and transna-
tional referral programs for continuity of TB therapy.
65.1.3. Strengthen partnerships between ICE and TB 
Programs in countries to which patients are deported while on 
TB treatment that was initiated in the United States.
Lead federal agencies: HHS (CDC and HRSA), USAID, 
DHS (ICE, CBP), federal courts, and USMS.
Suggested collaborators: foreign NTPs and ministries of 
health, local and state TB programs in the United States and 
other countries, Cure TB, and TB Net.
Cost Analysis
A realistic national estimate of the costs of diagnosing, treat-
ing, and managing XDR TB will be an important prerequisite 
for measuring the benefit and savings to the United States that 
would be realized through prevention of XDR TB. CDC has 
estimated the costs for hospitalization of one XDR TB patient 
at approximately $483,000 (CDC, unpublished data 2007) 
whereas outpatient treatment costs, productivity losses, patient 
out-of-pocket expenses, and quality of life changes attributable 
to XDR TB are unknown.
Some of the existing interventions and strategies for TB care 
and management, such as the use of DOT, already have been 
demonstrated to be cost effective in preventing the develop-
ment of MDR TB, but information about additional strategies 
is currently not available. Analysis of such cost-benefit and 
cost-effectiveness data will be critical to prioritize programs 
and advocate for resources to implement specific interventions 
to help prevent XDR TB.
Problem 66
A comprehensive and up-to-date estimate of the costs of 
diagnosing, treating, and managing XDR TB in the United 
States in not available.
objective 66.1
Conduct a study on the basis of health-care system and soci-
etal perspectives to calculate the costs of diagnosing, treating, 
and managing all cases of XDR TB identified through surveil-
lance for patients and their contacts (domestic).
Action Steps
66.1.1. Identify representative samples or cohorts of XDR TB 
patients during 2004–2007 (verified and reported, unreported 
incident and prevalent cases), and their contacts for estimating 
costs associated with health care and personal productivity.
66.1.2. Estimate from representative samples or cohorts of 
XDR TB patients the average medical costs incurred on the 
basis of the extent and pattern of drug resistance, medically 
indicated procedures and examinations needed to diagnose 
drug-resistant TB, the length of inpatient and outpatient 
treatment, management of adverse events and treatment and 
disease associated chronic sequelae, and the cost of case man-
agement of contacts.
66.1.3. Estimate from representative samples or cohorts of 
XDR TB patients that were employed prior or during XDR TB 
diagnosis associated losses in personal productivity and salary 
losses on the basis of the extent and pattern of drug resistance, 
chronic disease, and the impact of patient mortality (age at 
death and time to death).
66.1.4. From a survey of XDR TB survivors and their family 
members, estimate loss of quality-adjusted life years on the basis 
of extent and patterns of drug-resistant TB disease.
66.1.5. Conduct patient interviews to estimate out-of-pocket 
medical expenses associated with XDR TB disease.
Lead federal agencies: HHS (CDC).
Suggested collaborators: state/local Departments of Health, 
public and private outpatient providers and hospitals, labora-
tories, former patients, and family members.
Problem 67
Cost-effective strategies to prevent XDR TB remain to be 
established.
objective 67.1
Determine the costs of interventions or strategies to prevent 
XDR TB in the United States (domestic).
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Action Steps
67.1.1. On the basis of a review of the literature of recom-
mended interventions and strategies to prevent XDR TB in 
the U.S, identify those interventions and strategies that might 
offer the greatest cost effectiveness.
67.1.3. Determine implementation costs for interventions 
that have not previously been assessed.
67.1.4. Determine the cost benefit for each prevention 
strategy in relation to cost that would have been incurred to 
treat XDR TB.
Lead federal agencies: HHS (CDC).
Suggested collaborators: state and local health departments, 
and academia.
Conclusion
The nine response areas addressed in this report are closely 
aligned with WHO’s seven-point Global Action Plan to 
Combat XDR TB (26), which calls for public health authori-
ties to 1) conduct rapid surveys of XDR TB to determine the 
burden, 2) enhance laboratory capacity with an emphasis on 
rapid drug sensitivity testing, 3) improve technical capacity of 
clinical and public health practitioners to respond effectively 
to XDR TB outbreaks and manage patients, 4) implement 
infection-control precautions, 5) increase research support for 
TB drug development, 6) increase research support for rapid 
diagnostic test development, and 7) promote universal access 
to antiretroviral drugs under joint TB/HIV activities. 
The Federal TB Task Force Plan and the Global Action Plan 
will require a renewed commitment by all public health work-
ers as well as new resources from both the public and private 
sectors. In the United States, federal funding has remained 
relatively level since 2000, and state and local funding has 
declined in many states since 2000. As a result, TB preven-
tion and control capacity in the United States has eroded. For 
example, many states have decided to implement selective 
rather than universal patient-centered DOT to ensure adher-
ence to treatment until complete. These decisions are made 
on the basis of financial constraints but place the patient at 
high risk for treatment failure and subsequently the potential 
creation of MDR TB or XDR TB. In the absence of shorter 
treatment regimens, and without adherence-promoting mea-
sures such as DOT, the TB patient is more likely to experi-
ence drug resistance that could result from interruptions in 
treatment. These choices place the public and the nation in a 
vulnerable position, risking outbreaks of MDR or XDR TB if 
conditions facilitate rapid spread and possibly causing public 
health crises. (42,43)
The Federal TB Task Force Plan provides an effective frame-
work to detect, prevent, and control XDR TB, but it also 
highlights the existence of substantial unmet needs. There is 
concern that progress in TB prevention and control is wan-
ing as manifested by the decrease in the rate of decline in TB 
incidence since 2000. The United States responded success-
fully to the MDR TB problem in the 1990s and is capable 
of preventing and controlling XDR TB; however, this will 
require a united commitment and effort similar to that which 
occurred in 1992.
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Appendix
Acronyms and Abbreviations Used in This Report
AAFP American Academy of Family Physicians
ACCP American College of Chest Physicians
ACET  Advisory Council for the Elimination of Tuberculosis
AERAS Aeras Global TB Vaccine Foundation
AFB Acid fast bacillus
AIA American Institute of Architects
AIDS Acquired immunodeficiency syndrome
ALA American Lung Association
AM American Medical Association
APHL Association of Public Health Laboratories
APIC Association for Professionals in Infection Control and Epidemiology
ASHRAE American Society of Heating, Refrigerating and Air-Conditioning Engineers
ASM American Society for Microbiology
ASTHO  Association of State and Territorial Health Officers
ATS American Thoracic Society
BAMT Blood assays for Mycobacterium tuberculosis
BOP Federal Bureau of Prisons
CBP U.S. Customs and Border Protection
CLSI Clinical and Laboratory Standards Institute
DHS Department of Homeland Security
DIHS Division of Immigration Health Services
DOD Department of Defense
DOJ Department of Justice
DOS Department of State
DOT Directly observed therapy
DOTS Directly observed therapy, short-course
DR LTBI Drug-resistant latent tuberculosis infection
DST Drug susceptibility testing
DTBE Division of Tuberculosis Elimination
EQA External quality assurance
EU European Union
FDA Food and Drug Administration
FIC Fogarty International Center
FIND Foundation for Innovative New Diagnostics
FHI Family Health International
GLC Green Light Committee
HHS Department of Health and Human Services
HICPAC Hospital Infection Control Practices Advisory Committee
HIV Human immunodeficiency virus
HRSA Health Resources and Services Administration
HUD Department of Housing and Urban Development
ICE U.S. Immigration and Customs Enforcement
IDSA Infectious Diseases Society of America
IUATLD International Union Against Tuberculosis and Lung Disease
JCAHO Joint Commission (formerly Joint Commission on Accreditation of Healthcare Organizations)
KNCV Royal Netherlands Tuberculosis Association
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LTBI Latent tuberculosis infection
MDR TB Multidrug-resistant tuberculosis
MSF Doctors Without Borders/Medecins Sans Frontieres
NCET National Coalition for the Elimination of Tuberculosis
NGO Non-governmental organization
NIH National Institutes of Health
NLTN National Laboratory Training Network
NTCA National TB Controllers Association
NTCC National Tuberculosis Curriculum Consortium
NTP National TB Program
NTSS National TB Surveillance System
OHSA Occupational Safety and Health Administration
POC Point-of-contact
RIF Rifampin resistance 
RIT Research Institute of Tuberculosis
RTMCC Regional Training and Medical Consultation Center
RVCT Report of verified case of tuberculosis
SAMHSA Substance Abuse and Mental Health Services Administration
TAG Treatment Action Group
TB Tuberculosis
TST Tuberculin skin test
USAID U.S. Agency for International Development
USMS United States Marshals Service
UVGI Ultraviolet germicidal irradiation
VA Department of Veterans Affairs
WHO World Health Organization
WHO (TDR) World Health Organization Research and Training in Tropical Diseases
XDR TB Extensively drug-resistant tuberculosis
Vol. 58 / RR-3 Recommendations and Reports 43
Federal Tuberculosis Task Force
Membership List as of March 2007
Co-chairs: Kenneth G. Castro, MD, CDC; Christine Sizemore, PhD, National Institutes of Health, Bethesda, Maryland.
Members: John Bernardo, MD, National Tuberculosis Controllers Association, Boston, Massachusetts; Amy Bloom, MD, Christy Hanson, PhD, U.S. Agency 
for International Development, Washington, District of Columbia; Michael Brennan, PhD, Food and Drug Administration, Bethesda, Maryland; Kenneth 
Bridboard, MD, Henry “Skip” Francis, MD, Robert Goldman, PhD, Gail Jacobs, MA, MS, ; Jag Khalsa, PhD, Elizabeth Lambert, MSc, Chris Lambros, Barbara 
Laughon, PhD, Mamodikoe Makhene, MD, Jeanne McDermott, PhD, Hannah H. Peavy, MD, Rebecca D. Prevots, PhD, Karl A. Western, MD, DTPH, 
National Institutes of Health, Bethesda, Maryland; Sarah Bur, MPH, Federal Bureau of Prisons, Baltimore, Maryland; William J. Callan, PhD, Association 
of Public Health Laboratories, Montgomery, Alabama; James Cheek, MD, Indian Health Service, Albuquerque, New Mexico; Barbara Sina, Phillip Smith, 
MD, Indian Health Service, Rockville, Maryland; Maria Dinger, MS, U.S. Public Health Service, Washington, District of Columbia; Alice Fike, MSN, Diana 
Schneider, DrPH, Department of Homeland Security, Washington, District of Columbia;; James Hadler, MD, Association of State and Territorial Health 
Officers, Hartford, Connecticut; Harry Haverkos, MD, Sheldon Morris, PhD, Melford J. Henderson, MA, MPH, Leonard Sacks, MD, Roxanne G. Shively, 
MS, Food and Drug Administration, Rockville, Maryland; Warren W. J. Hewitt, Substance Abuse and Mental Health Services Administration, Rockville, 
Maryland; Newton Kendig, MD, Federal Bureau of Prisons; Washington, District of Columbia; Donna Olive, MS, Federal Bureau of Prisons, Washington, 
District of Columbia; Lee Reichman, MD, FACP, FCCP, New Jersey Medical School National Tuberculosis Center, Newark, New Jersey; Gary Roselle, MD, 
Department of Veterans Affairs Medical Center, Cincinnati, Ohio; Sarah Royce, MD, California Department of Health Services, Berkeley, California; David 
Vos, U.S. Department of Housing and Urban Development, Washington, District of Columbia; Charles Wallace, PhD, Texas Department of Health, Austin, 
Texas; Theresa Watkins-Bryant, MD, FAAP, Health Resources and Services Administration, Rockville, Maryland; Anstice Brand, Michael Craig, MPH, CDC, 
Washington, District of Columbia; Drew L. Posey, MD, John Ridderhof, DrPH, Teresa Durden, MPA, Kevin Fenton, MD, PhD, Mary Naughton, MD, 
Rachel Albalak, PhD, Marcia Brooks, MA, Ann Cronin, Philip LoBue, MD, FACP, FCCP, Bess Miller, MD, Thomas R. Navin, MD, Tom Shinnick, PhD, 
Phillip Talboy, Andrew, Vernon, MD, Wanda Walton, PhD, Charles Wells, MD, Maureen Wilce, MS, CDC, Atlanta, Georgia.


U.S. Government Printing Office: 2009-523-019/41153 Region IV ISSN: 1057-5987
 MMWR 
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of 
charge in electronic format. To receive an electronic copy each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read SUBscribe 
mmwr-toc. Electronic copy also is available from CDC’s Internet server at http://www.cdc.gov/mmwr or from CDC’s file transfer protocol server at ftp://ftp.cdc.
gov/pub/publications/mmwr. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, 
DC 20402; telephone 202-512-1800.
Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business 
on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public 
Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the MMWR Series, including material to be considered 
for publication, to Editor, MMWR Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to mmwrq@cdc.gov. 
All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human 
Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations 
or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses 
listed in MMWR were current as of the date of publication.
